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Introduction
Lung cancer is the most commonly diagnosed cancer world-wide (1.61 million; 12.7% of 
the total) and also the leading cause of cancer death (1.38 million; 18.2% of the total) (1). 
In the Netherlands, lung cancer was diagnosed in almost 11,000 patients in 2007 (website 
Netherlands Cancer Registry; www.ikcnet.nl). The majority of these patients (77%) have 
non-small cell lung cancer (NSCLC) and of these patients approximately 20% present with a 
resectable tumor (website Netherlands Cancer Registry; www.ikcnet.nl). Although surgery is 
the treatment of choice for patients with resectable tumors, many patients are inoperable due 
to smoking-related comorbidity. These patients were commonly treated with conventional 
radiotherapy (≥60 Gy in 2 Gy fractions), but the results were disappointing (51% local tumor 
control rate and a 15% survival rate at 5 years) (2, 3). Stereotactic body radiotherapy (SBRT) 
is an alternative treatment currently used for inoperable patients with stage I NSCLC. SBRT 
delivers a high radiation dose to the tumor in a small number of fractions over a short overall 
treatment time (typically 48-60 Gy in 3-6 fractions). Although the total dose may seem equal 
to that in conventional radiotherapy, the high dose per fraction of SBRT (20 Gy versus 2 Gy) 
is biologically more potent. Thus the biological effective dose (BED) is greater in SBRT than 
in conventional radiotherapy (BED >100 Gy versus 60 Gy). 
Stereotactic body radiotherapy enables the delivery of high radiation doses to the tumor 
while restricting the dose to healthy tissues as 1) the radiation dose distribution conforms 
to the tumor shape and has a steep dose fall off and 2) geometric uncertainties in tumor 
targeting are reduced so that a smaller “safety” margin of healthy tissue is irradiated. In 
conventional radiotherapy a large safety margin of healthy tissue is typically irradiated to 
account for variations in patient set-up and tumor delineation, but also to account for tumor 
motion. Technical advances in SBRT have reduced geometrical uncertainties. The accuracy 
of patient set-up has been improved by the development of in-room imaging modalities such 
as stereoscopic x-ray systems or linac-integrated cone beam CT-scans (kV or MV). These 
modalities allow patient set-up to be based on images of the tumor position, or structures 
located near the tumor rather than on external skin-marks. Another challenging source of 
geometric uncertainty especially relevant to SBRT is tumor motion in the lung. Different 
approaches have been used to account for tumor motion including 1) the use of individual-
ized margins to account for patient specifi c tumor motion, 2) breath-holding 3) abdominal 
compression 4) respiratory gating and 5) real-time tumor tracking. Breath-holding and 
abdominal compression both aim to reduce the extent of tumor motion. During respiratory 
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gating, radiation exposure is limited to a part of the breathing cycle. During real-time tumor 
tracking, the radiation beam follows the movement of the tumor and irradiates the tumor 
throughout the breathing cycle.
At the Erasmus Medical Center in Rotterdam the CyberKnife real-time tumor tracking 
system was used to treat patients with stage I NSCLC. The CyberKnife is a frameless stereo-
tactic radiotherapy system that involves a light-weight 6 MV linear accelerator mounted on 
a highly mobile robotic arm and a real time image guidance system (Figure 1). The image 
guidance system consists of stereoscopic kV x-ray sources and a synchrony camera that re-
cords the motion of red-light emitting diodes attached to the patient’s chest. The CyberKnife 
real-time tumor tracking system corrects for tumor motion by repositioning the radiation 
beam to the position of the moving tumor. As the tumor is not often directly visible dur-
ing treatment, radio-opaque markers are inserted in or near the tumor and act as surrogates 
for tumor position. These markers can be placed via bronchoscopy, via the percutaneous 
Linear accelerator
Robot arm
kV X-ray tube
Synchrony camera
Red light emitting diodes
Flat-panel 
detectors
Figure 1. The CyberKnife real-time tumor tracking system.
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intrapulmonary approach or via the vascular approach using embolisation coils. The location 
of these implanted markers is determined by a series of kV stereoscopic x-ray images taken 
during respiration. At the same time, motion of red-light emitting diodes on the patient’s 
chest is registered and correlated to the location of the implanted markers. The resulting 
correspondence model is used to move the robot arm and direct the radiation beam at the 
moving tumor.
Aim of this thesis
As the position of radio-opaque markers are used to direct the radiation beam at the tumor, 
accurate delivery of radiation is only possible if the position of the markers relative to the 
tumor is stable. A concern regarding tumor localization is that markers may migrate from 
their initial position, or that the surrounding tissues may swell or deform during treatment. 
In chapter 2 we determined the stability of markers placed in or near the lung tumor via 
the percutaneous intrapulmonary approach. In addition we assessed whether a change in 
distance between markers is a reliable check for displacement of the center of mass of the 
marker confi guration relative to the tumor position. 
In chapter 3 we evaluated the clinical outcome of SBRT using real-time tumor tracking in 
stage I NSCLC patients. The local tumor control rate, overall survival, treatment related 
toxicity and toxicity related to marker placement were determined. These treatment out-
comes were compared to those achieved using other SBRT techniques. Chapter 4 focuses 
on the clinical outcome of SBRT in octogenarians with stage I NSCLC. As life expectancy 
increases, more octogenarians will present with stage I NSCLC. Merely carefully selected 
subsets of octogenarians are treated with surgery, and the postoperative morbidity and mor-
tality are not negligible (4-6). Therefore it is of great interest to determine the outcome of 
SBRT in octogenarians.
Although local tumor control rates above 90% have been achieved in stage I NSCLC patients 
treated with SBRT (7-9), an equally important aim is to maintain or improve the patient’s 
quality of life. Given the high level of comorbidity in many patients with NSCLC and the 
limited overall survival, we assessed the impact of SBRT on the patient’s quality of life in 
chapter 5. 
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Lastly chapter 6 considers the clinical implementation of the more accurate Monte Carlo 
dose calculation algorithm. Unlike the equivalent pathlength algorithm (EPL), Monte Carlo 
dose calculation accounts for decreased attenuation of the primary photon beam in low 
density lung tissue but also for the increased electron range. For this reason, doses to the 
planning target volume and organs at risk are lower for Monte Carlo than for EPL calcula-
tion. To enable treatment planning using the more accurate Monte Carlo dose calculation 
algortithm in the future, we compared dose distributions calculated with EPL and MC and 
proposed a MC prescription dose according to tumor size and location.
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Abstract
Purpose
To determine the stability of markers used for real-time tumor tracking after percutaneous 
intrapulmonary placement.
Methods
Forty-two patients with 44 lesions, 111 markers and ≥2 repeat CT-scans were studied. The 
tumor in repeat CT-scans was registered to the tumor in the planning CT-scan. Next, the 
three-dimensional marker coordinates were determined on the planning CT-scan and the 
repeat CT-scans. Marker stability was analysed by the displacement of markers and the dis-
placement of the center of mass (COM) of marker confi gurations. In addition, we assessed 
the reliability of using inter-marker distance as a check for displacements in the COM of the 
marker confi gurations.
Results
Median marker displacement was 1.3 mm (0.1-53.6 mm). Marker displacement exceeded 
5 mm in 12% of markers and 10 mm in 5% of markers. Causes of marker displacement >5 
mm were marker migration (2 of 13) and target volume changes (5 of 13). Non-synchronous 
tumor and marker movement during breathing may be responsible for displacements >5 mm 
in the other 6 of 13 markers. Median displacement in the COM of marker confi gurations was 
1.0 mm (0.1-23.3 mm). Displacements in the COM of marker confi gurations ≥2.0 mm were 
detected by changes in the inter-marker distance of >1.5 mm in 96% of treatment-fractions.
Conclusion
The median marker displacement was small (1.3 mm). Nevertheless, dislpacements >5 mm 
ocurred in 12% of the markers. Therefore, we recommend the implantation of multiple 
markers as multiple markers will enable a quick and reliable check for marker diplacement 
by determining the change in the intermarker distance. A displacement in the COM of the 
marker confi guration of ≥2.0 mm was almost always detected (96%) by a change in the 
distance between the markers of >1.5 mm. This enabled the displaced marker to be disabled, 
such that tumor localization was not compromised.
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Introduction
Stereotactic body radiotherapy (SBRT) delivers escalated doses to the tumor using tight 
margins and a highly conformal dose distribution. As such, accurate tumor localization is 
required to prevent under dosage of the tumor or over dosage of the organs at risk. Several 
approaches can be used to localize the tumor during SBRT. These approaches include the 
use of cone-beam computed tomography (CBCT) imaging, electronic portal imaging and 
stereoscopic kilovoltage x-ray imaging. As electronic portal imaging and stereoscopic kilo-
voltage x-ray imaging rarely allow direct tumor localization, a surrogate is often required 
to determine the three-dimensional tumor location. Surrogates such as the bony anatomy or 
the position of anatomic landmarks (carina/diaphragm) can be used depending on the tumor 
site and location. The use of these surrogates to determine tumor position may however 
be inaccurate due to intra-fraction and inter-fraction variations in the relationship between 
surrogate structures and the tumor (1). A more direct way to detect tumor position is the use 
of markers implanted in or near the tumor. 
At our institute, implanted markers are often used as a surrogate for the position of stage I 
non-small cell lung cancer (NSCLC) tumors during CyberKnife stereotactic radiotherapy. In 
order to accurately target the tumor, it is essential that the position of the implanted markers 
remains stable relative to the position of the tumor. Concerns regarding tumor localization 
based on implanted markers are that markers may migrate from their initial position, or that 
the surrounding tissues may swell or deform during treatment. 
Two studies previously examined the stability of implanted markers during treatment. The 
fi rst study assessed the stability of 1.5 mm gold markers implanted via bronchoscopy in 11 
patients (2). These 11 patients had been selected from a total of 57 patients, and did not in-
clude those patients in whom markers were displaced after bronchoscopy but before the fi rst 
fraction of radiotherapy. The second study examined the stability of a 2.0-cm long marker 
placed in the lung tumor via bronchoscopy in 8 patients and via the percutaneous intrapulmo-
nary approach in 15 patients (3). Similar to this second study, we also placed markers via the 
percutaneous intrapulmonary approach. However, we used a smaller 4.0-mm long platinum 
marker and multiple markers were placed for the majority of tumors. The toxicity related 
to percutaneous implantation of the 4.0 mm platinum markers has been reported previously 
(4, 5). The aim of the present study was to determine the stability of the 4.0 mm platinum 
markers placed via the percutaneous intrapulmonary approach in 42 patients. In addition to 
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this, we assessed whether a change in distance between markers is a reliable check for the 
displacement of the COM of the marker confi guration relative to the tumor.
Methods
Patient selection and marker placement
Patients were included in this study if markers were placed via the percutaneous intrapul-
monary approach. Percutaneous intrapulmonary marker placement was performed under 
local anaesthesia by an experienced radiation oncologist or an intervention radiologist. An 
eighteen gauge needle was used to place markers in or near the tumor under fl uoroscopic-, 
CT- or ultrasound guidance. Ideally three platinum markers were placed. The smooth mark-
ers were 4.0 mm long and had a diameter of 0.9 mm. Markers were manufactured in house 
using platinum-thread delivered by Drijfhout, Amsterdam. As percutaneous marker place-
ment may be complicated by a pneumothorax or haemorrhage, two anteroposterior chest 
radiographs were made; one directly after the procedure, and one an hour later. 
Approximately one week after marker placement, an exhale breath-hold treatment planning 
CT-scan was made. The planning CT-scan had a slice thickness and spacing of 1.5-2.0 mm. 
Details concerning treatment planning have been described previously (6). Briefl y, the gross 
tumor volume (GTV) was contoured using lung window. Planning target volume (PTV) = 
GTV + 5 mm. Patients with peripheral tumors were treated with 3 x 20 Gy. Patients with 
central tumors (7) were treated with 6 x 8 Gy if the tumor was located near the oesophagus 
or 5 x 12 Gy for all other central tumors.
Registration of Repeat CT-scans 
During the treatment course, repeat CT-scans were made using the same settings as the 
planning CT-scan (exhale breath-hold). Repeat CT-scans were made prior to each treatment 
fraction in patients with peripheral tumors (repeat CT-1, CT-2 and CT-3); and prior to the 
fi rst, third and last treatment fraction (repeat CT-1, CT-2 and CT-3) in patients with central 
tumors. For the purpose of this study, we registered the tumor in the repeat CT-scans to 
the tumor in the planning CT-scan. A two step-approach was used for registration; fi rst an 
automated registration was performed on a region of interest including the gross tumor 
volume (GTV) and a minimal volume of surrounding normal lung tissue. The cost function 
of the registration used the root-mean-square difference in grey values as a metric. The 
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registration included both translations and rotations (fi gure 1). The second step involved a 
visual check of each registration based on reference structures in or near the tumor (bronchial 
trees or pulmonary vessels). The uncertainty related to the registration of the CT-scans was 
expected to be approximately 0.75-2.0 mm. Once the CT-images had been registered, we 
determined the three-dimensional coordinate of each marker on the planning CT-scan and 
the corresponding marker coordinate on the repeat CT-scan.
Planning CT-scan Repeat CT-scan
+
Registered CT-scans
x
xƍ
xƍ
x
Figure 1. Registration of the planning CT-scan and the repeat CT-scan. The markers are represented by 
black dots in the planning CT-scan and open squares in the repeat CT-scan. The center of mass of the 
marker confi guration is indicated by an X in the planning CT-scan and X′ in the repeat CT-scan. 
Marker stability assessment
Marker stability was fi rst assessed by the displacement of individual markers. The displace-
ment of an individual marker was defi ned by the vector connecting the marker coordinate 
in the planning CT-scan and the corresponding marker coordinate in the repeat CT-scan. If 
individual markers were displaced by >5.0 mm, we visually inspected the CT-registrations 
to examine the cause of marker displacement. Marker displacement was compared 1) for 
markers placed in the tumor versus outside the tumor, and 2) for markers of central tumors 
versus peripheral tumors. We also evaluated whether marker displacement was affected by 
the time between the planning CT-scan and the repeat CT-scans. 
Next, marker stability was assessed by the displacement of the COM of the marker confi gu-
ration. This was done because CyberKnife tumor localization is based on the COM of the 
marker confi guration. First, the COM of the marker confi guration was determined on the 
planning CT-scan and on the repeat CT-scans by calculating the average of the individual 
marker coordinates on these CT-scans. Next, the displacement of the COM coordinates 
of the marker confi guration was determined by calculating the vector between the COM 
coordinates on the planning CT-scan and the repeat CT-scan. 
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Finally, we assessed whether a change in distance between markers could reliably detect a 
displacement of the marker confi guration relative to the tumor. Patients with at least two 
markers were included in this analysis. As a quality assurance check, the CyberKnife tumor 
tracking system generates a warning if the distance between markers has deviated by >1.5 
mm from the reference confi guration in the planning CT-scan. This warning allows the 
physician to identify and disable the displaced marker or to increase the tolerated deviation 
from 1.5 mm to a maximum of 5.0 mm. We determined whether a relevant displacement 
in the COM of the marker confi guration (≥2.0 mm) was accompanied by a change in the 
distance between markers of >1.5 mm. A displacement in the COM of the marker confi gura-
tion of ≥2.0 mm was considered relevant. This value (≥2.0 mm) was chosen to account for 
the uncertainty related to the registration of the CT-scans. Marker COM displacements of 
≥2.0 mm were also considered clinically relevant because 2.0 mm has been used for other 
uncertainties such as the respiratory tumor tracking uncertainty (determined largely by the 
correlation model error). The respiratory tumor tracking error was 1.2 mm (vector of the 
mean correlation model error) (8) .
Statistical Analysis
Multi-lever mixed-effects linear regression was used to evaluate the association between 
marker displacement and 1) the location of the marker (inside versus outside the tumor), 
2) the location of the tumor (peripheral versus central) and 3) the time between the repeat 
CT-scan and the planning CT-scan. All p-values are two-sided, and a signifi cance level α = 
0.05 was used.
Results
Patient selection
Thirty-eight patients with 40 tumors had three repeat CT-scans while four patients with four 
tumors had two repeat CT-scans. The average time between marker placement and the plan-
ning CT-scan was 9 ± 4 days (range: 3-26 days). The average time between the planning 
CT-scan and the repeat CT-scan was 8 ± 3 days for CT-1, 11 ± 3 days for CT-2 and 14 ± 4 
days for CT-3. One-hundred and eleven markers were placed in total and 80% of the tumors 
(35/44) had two or more markers placed either in or near the tumor. None of the implanted 
markers were coughed-up between implantation and the planning CT-scan. P atient, tumor 
and marker characteristics are listed in table 1.
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Table 1. Patient and tumor characteristics.
Gender
 Male
 Female
32 
10 
Tumor size (cm)
 mean
 range
4.2
1.0-10.5
Tumor location
 Right upper lobe
 Right middle lobe
 Right lower lobe
 Left upper lobe
 Left lower lobe
11 (25%)
5 (11%)
9 (20%)
13 (30%)
6 (14%)
Peripheral tumor location
Central tumor location
31 (70%)
13 (30%)
Markers detected on the planning CT-scan 111 (100%)
Number of markers per tumor
 1
 2
 3
 4
9 (21%)
10 (23%)
18 (41%)
7 (16%)
Marker location
 Inside the tumor
 Outside the tumor
58 (52%)
53 (48%)
Registration of Repeat CT-scans
The average rotational adjustment during automatic registration was 0.2 ± 3º (range: -11-
16º). In merely 4 of 44 tumours, manual adjustments were made after automated registration 
of one or more repeat CT-scans. Manual adjustments were made due to changes in tumor 
volume/shape.
Marker stability
The median displacement of markers was 1.1 mm on CT-1 (range: 0.2- 20.7 mm), 1.2 mm 
on CT-2 (range: 0.1- 25.4 mm) and 1.3 mm on CT-3 (range: 0.3- 53.6 mm) (fi gure 2). The 
displacement of markers along any anatomical axis is given in table 2. Marker displacement 
exceeded 5 mm in 13 of 111 markers (12%) placed in nine patients. Marker displacement 
exceeded 10 mm in 5 of 111 markers (4%) placed in four patients. These markers were 
displaced by more than 5 or 10 mm, in one or more repeat CT-scans. 
Upon visual inspection of the CT-registration, the cause of marker displacement >5 mm was 
marker migration (2/111; 2%), tumor regression (4/111; 4%), tumor deformation (1/111; 1%) 
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Figure 2. Displacement of individual markers in the repeat CT-scans. 
Table 2. Displacement of individual markers (mm) in the repeat CT-scans.
CT-1 CT-2 CT-3
Left-Right
 Average -0.1 0 -0.1
 SD 1.9 2.2 3.2
 Range -15.9 – 3.9 -20.1 – 4.5 -28.2 – 8.6
Cranio-caudal
 Average -0.3 -0.2 -0.4
 SD 1.9 2.2 3.2
 Range -13.1 – 3.8 -14.8 – 6.3 -22.7 – 4.5
Anterior-posterior
 Average 0 0.5 -0.2
 SD 1.3 1.6 4.4
 Range -4.6 – 3.6 -3.0 – 7.2 -41.7 – 5.8
Average 3D- distance (SD) 1.9 (2.6) 2.0 (3.1) 2.8 (5.8)
SD: standard deviation; 3D: three-dimensional
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and possibly non-synchronous tumor-marker motion (6/111; 5%). Two markers had migrated 
relative to the tumor and the surrounding structures in one patient. Four markers placed in 
three tumors were displaced due to tumor regression. Finally, one marker was displaced due 
to tumor deformation (this tumor had changed shape without a visually evident regression 
in tumor volume). For the remaining six markers, a clear cause of marker displacement >5 
mm could not be identifi ed. For fi ve markers with a displacement >5 mm, the CT-registration 
showed an accurate tumor match, but also a slight respiratory phase difference (difference 
in the position of the ribs, diaphragm and vertebra). These markers may have moved 
non-synchronously to the tumor. The fi ve markers were all placed furthest from the tumor 
compared to the other implanted markers (table 3). For the sixth marker, a respiratory phase 
difference was not evident between the planning CT-scan and the repeat CT-scan. We did 
however observe a pulmonary infi ltrate on the repeat CT-scan, which may have infl uenced 
the motion of the marker but not that of the tumor.
Marker position (in or near the tumor) and tumor location (peripheral or central) did not 
signifi cantly infl uence marker displacement. An increase in the time between the planning- 
and the repeat- CT-scan signifi cantly increased the displacement of markers (p <0.01). The 
magnitude of this effect was small (0.30 mm/day; 95% CI: 0.21-0.38 mm/day). 
Table 3. Causes of marker displacement based on visual inspection of the CT-registration
Patient Marker
(location)
Displacement (mm) Cause Marker - Tumor 
Distance§ (mm)
Tumor diameter 
(mm)
1 1 (O) 5.3 * 83.7 32.0
2 2 (O) 5.3 * 36.1 32.0
3 3 (O) 6.1 * 27.3 27.0
4 4 (O) 9.3 * 30.0 25.0
4 5 (O) 6.8 * 31.2 25.0
5 6 (O) 12.5 * 37.3 69.0
5 7 (I) 5.3 Tumor regression 26.0 69.0
6 8 (I) 10.4 Tumor regression 36.8 100.5
6 9 (I) 8.1 Tumor regression 35.0 100.5
7 10 (I) 10.9 Tumor regression 29.6 63.0
8 11 (O) 6.1 Tumor deformation 32.7 83.0
9 12 (I) 53.6 Migration 9.5 63.0
9 13 (I) 23.8 Migration 6.2 63.0
* Cause of displacement is uncertain. Marker may have been displaced by non-synchroon tumor-marker motion.
§ Marker- Tumor distance is the distance between the center of mass of the tumor and the center of the marker.
(O) located outside the tumor; (I) located inside the tumor
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The median displacement of the COM of marker confi gurations was similar to the median 
displacement of individual markers (1.0 mm in all three CT-scans versus 1.1-1.3 mm). How-
ever, the maximum displacement of the COM of marker confi gurations was much smaller 
than the maximum displacement of individual markers: (7.4 mm versus 20.7 mm in CT-1, 
8.2 mm versus 21.0 mm in CT-2, and 23.3 mm versus 53.6 mm in CT-3) (fi gure 3). The COM 
was displaced by >5 mm in 3 of 44 marker confi gurations (7%). These marker confi gurations 
were displaced by >5 mm in merely one CT-registration (n=2) or in all three CT-registrations 
(n=1). The COM of one marker confi guration was displaced by more than 10 mm in one 
repeat CT-scan. 
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Figure 3. Displacement of the center of mass of the marker confi gurations in the repeat CT-scans.
Thirty-four patients with 35 tumors had at least two markers and were included in the analy-
sis; “Is the change in distance between markers a reliable check for displacements in the 
COM of the marker confi guration relative to the tumor position?”. One-hundred-and-two 
CT-scan registrations were available as 31 patients with 32 tumors had 3 repeat CT-scans 
(n= 96) while 3 patients with 3 tumors had 2 repeat CT-scans (n= 6). A displacement in the 
COM of the marker confi guration of ≥2.0 mm was accompanied by a detectable change in 
the distance between markers of >1.5 mm in all but 4% of the CT-registrations (4/102). A 
displacement of the COM of the marker confi guration of ≥3.0 mm was accompanied by 
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a detectable change in the distance between markers of >1.5 mm in all but 1% of the CT-
registrations (1/102) (fi gure 4). In one CT-registration, the change in the COM of the marker 
confi guration was 7 mm but the change in distance between markers was only 2 mm (fi gure 
4). Despite this, an error in tumor targeting did not occur. The marker confi guration was a 
mirror image of the original confi guration; thus, the CyberKnife system could not recognize 
the original marker confi guration on the stereoscopic x-ray images. 
Fi gure 4. Change in the center of mass (COM) of the marker confi gurations and the corresponding 
maximum change in inter-marker distance (IMD). Changes in marker confi guration COM of ≥2 mm were 
considered relevant (above the grey shaded area). Open circles represent undetected changes in the COM, 
while solid circles represent detected changes.
Discussion
Our results have shown that the median displacement of markers placed via the percutaneous 
intrapulmonary approach is 1.3 mm during treatment. However, marker displacements >5 
mm occurred in 12% of markers (13/111). Visual inspection revealed that displacements >5 
mm did not necessarily refl ect marker migration. 
Large marker displacements were also caused by tumor regression and deformation, and 
perhaps by non-synchronous tumor-marker motion. Although lung tumors frequently regress 
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during conventional radiotherapy (9, 10), previous stereotactic radiotherapy studies merely 
observed slow tumor regression (11, 12). In our study, only a minority of tumors signifi cantly 
changed in volume/shape (4/44; 9%). In these tumors, the short onset of regression was per-
haps related to tumor-specifi c characteristics and/or the delivery of 3-5 high fraction doses 
within one week. None of the reductions in tumor volume were related to the disappearance 
of atelectasis. Besides tumor regression/deformation, large marker displacements may have 
been caused by non-synchronous tumor-marker movement. In six of 13 markers, a defi nite 
cause for marker displacements >5 mm could not be identifi ed. These markers may have mi-
grated. A plausible alternative is that these markers moved non-synchronously to the tumor. 
The six markers were the most distal markers from the tumors (2.7 – 8.4 cm away from the 
center of the tumor). As such, the risk of non-synchronous tumor-marker motion may be 
related to the distance between the marker and the tumor. However, further research using 
four-dimensional respiratory correlated CT-scans is required to 1) determine the extent of 
non-synchronous tumor- marker motion during respiration, and 2) assess whether a greater 
tumor-marker distance increases the risk of non-synchronous tumor-marker motion. 
As large marker displacements may occur, a reliable check for marker displacement is re-
quired in order to reduce the risk of inaccurate tumor localization. The CyberKnife real-time 
tumor tracking system localizes the tumor based on the COM of the marker confi guration. 
Large COM displacements were however observed in some fractions (up to 23.3 mm; me-
dian 1.0 mm). Therefore we recommend a reliable check for displacements in the marker 
confi guration COM prior to each treatment fraction. Our results have shown that the change 
in distance between markers is a reliable check for displacements in the COM of the marker 
confi guration relative to the tumor. Displacements in the COM of the marker confi guration 
of  ≥2.0 mm were almost always accompanied by a change in the distance between markers 
of >1.5 mm. As the CyberKnife tumor tracking system generates a warning if the distance 
between markers deviates by >1.5 mm from the reference confi guration, marker confi gura-
tion COM displacements of ≥2.0 mm will be detected in the majority of cases. Thus, the 
displaced markers can be identifi ed and the tumor can be localized using the remaining stable 
markers. Displacements smaller than 2.0 mm can be accounted for by the 5-mm GTV-PTV 
margin. We do not advise increasing the margin such that for all or nearly all patients the 
tumor is covered adequately even with the occurence of large marker migration. Instead, it is 
our policy to disable the displaced marker. 
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A previous study reported the fi xation rate of 1.5 mm gold markers after bronchoscopic 
placement in 57 patients with peripheral lung cancer (2). Merely 122 of the 154 implanted 
markers (79%) could be detected at treatment planning compared with 100% in our study 
(table 1). The rate of marker fi xation was higher for peripheral tumors than for central tu-
mors. Imura et al. hypothesized that the rate of marker fi xation depended on the diameter of 
the marker in relation to the bronchus (2). Perhaps the fi xation rate was higher in our study 
as larger markers (4.0 mm versus 1.5 mm) were used in mostly peripheral tumors (smaller 
bronchi diameter). Imura et al. also studied the stability of markers during treatment in 11 of 
the 57 patients (2). The change in distance between markers was much smaller than in our 
study (≤2.0 mm in 95% of cases versus ≤6.2 mm in 95% of cases). However, the analysis 
did not include those patients in whom a marker migrated after treatment planning (7/122 
markers, 6%). In addition to this, the stability of markers during treatment was assessed in 
a small number of patients (n=11). The number of markers placed in these 11 patients was 
not mentioned (2). 
The average displacement of the markers used in our study is similar to the displacement of 
a 2.0 cm-long marker placed in lung tumors via the percutaneous intrapulmonary approach 
(n=15 markers) or via the bronchoscopic approach (n=8 markers) (3). The average displace-
ment of the 2.0 cm-long marker was 2.6 mm compared with 2.8 mm in our study. The maxi-
mum displacement was however much lower than in our study (5.4 mm versus 53.6 mm). 
The authors stated that marker displacements >5.4 mm were probably not observed because 
the 2.0 cm-long marker is more likely to get wedged in the lung than smaller markers. We 
clearly observed migration in two markers, and possibly in another 6 markers, for which the 
cause of displacement was unclear (n=2-8/111). Although the 4.0 mm-long markers used in 
our study may be more susceptible to migration than the 2.0 cm-long markers, this cannot be 
concluded based solely on the present results. In our study, non-synchronous tumor-marker 
motion may have caused displacements ≥5 mm in 6 markers. Non-synchronous tumor-marker 
motion was probably not an issue for the 2.0 cm-long marker as this marker was placed into 
or directly bordering the tumor. In addition, it should be noted that the sample size of the 
2.0 cm-long marker study is much smaller than our sample size (23 markers versus 111 
markers). Thus the lower migration rate of the 2.0 cm-long marker may be coincidental. 
It is debated whether a single or multiple markers should be used for stereoscopic x-ray 
guided radiotherapy (13). Based on our results, we recommend the use of multiple mark-
ers. An advantage of using multiple markers is that marker displacements can be easily 
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detected on x-ray images through changes in the marker confi guration. This is not possible if 
a single marker is used. Displacements of a single marker may remain undetected and cause 
systematic localization errors. Some may argue that large marker displacements are rare. We 
observed displacements >5 mm in 12% of markers. The incidence of maker displacement 
may be high in our study due to non-synchronous tumor-marker motion (as some markers 
were located >2 cm from the tumor). On the other hand, the largest displacements occurred 
when markers were placed inside the tumor. These displacements were not only limited to 
the fi rst week after implantation; a time interval considered suffi cient for fi xation/fi brosis of 
the marker. Implantation of multiple markers also enables the detection of changes in tumor 
volume and shape. Although tumor volume and shape changes are less relevant in small lung 
tumors, it is possible to adapt the treatment plan in those cases where large target volume 
changes occur. 
An argument against the use of multiple markers is the higher risk of a pneumothorax when 
multiple markers are implanted. The risk of pneumothorax after marker placement is not neg-
ligible (ranging from 17-53%) (3, 5). The development of transbronchial, trans-oesophageal 
and vascular marker placement techniques has however reduced the risk of pneumothorax 
(14-16). In the absence of these alternative techniques, one should consider, per patient, 
whether the higher risk of pneumothorax still justifi es the use of multiple markers. If this risk 
is unacceptable, then four-dimensional respiratory-correlated CT-scans should be made prior 
to each treatment fraction in order to assure that the single marker remains stable relative to 
the tumor. At our institute, markers are frequently placed via the intravascular approach. An 
interesting question is whether marker displacement depends on the technique of implanta-
tion. Although we have not yet examined this, marker coils placed via the intravascular 
approach are probably more stable. These coils have been used extensively in neurosurgical 
clipping of aneurysms, and migration of endovascular coils has not been described (17). 
A limitation of our study is the accuracy of localizing the markers. Identifi cation of the center 
of the marker is limited by the slice thickness and spacing of the CT-scan. In our study the 
CT-scan slice spacing was 1.5-2.0 mm. Therefore the uncertainty in the CT-measurement 
was at best 0.75-1.0 mm. As such, the actual displacement of individual markers may be 
smaller than the median displacement of 1.3 mm stated in our “Results”  section. 
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Conclusion
Intrapulmonary markers are generally stable as the median marker displacement was small 
(1.3 mm). However, marker displacements >5 mm occurred in 12% of markers. To reduce 
the impact of marker displacement on tumor localization, we recommend the implantation of 
multiple markers. Multiple markers enable a quick and reliable check for displacement in the 
COM of the marker confi guration by determining the change in inter-marker distance. In the 
majority of cases (96%), a displacement in the COM of the marker confi guration of ≥2.0 mm, 
is detected by a change in the distance between markers of >1.5 mm. This allows displaced 
markers to be disabled such that tumor localization is not compromised.
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Abstract
Purpose
To report the clinical outcome of treatment using real-time tumor tracking for 70 patients 
with inoperable stage I non-small cell lung cancer (NSCLC).
Methods
Seventy inoperable patients with peripherally located early stage NSCLC were treated with 
45 or 60 Gy in 3 fractions using the CyberKnife. Pathology was available in 51% of patients. 
Thirty-nine patients had a T1-tumor and thirty-one had a T2-tumor. Markers were placed 
using the vascular, percutaneous intra-, or extra-pulmonary approach, depending on the risk 
of pneumothorax.
Results 
The actuarial 2-year local control rate for patients treated with 60 Gy was 96%, compared 
to 78% for patients treated with a total dose of 45 Gy (p=0.197). All local recurrences (n=4) 
occurred in patients with T2-tumors. Overall survival for the whole group at two years was 
62% and the cause specifi c survival was 85%. The median follow-up was 15 months. Grade 
3 toxicity occurred in two patients (3%) after marker placement. Treatment-related late grade 
3 toxicity occurred in 7 patients (10%). No grade 4 or 5 toxicity occurred.
Conclusion
Excellent local control of 96% at 1- and 2-years was achieved using 60 Gy in 3 fractions for 
NSCLC patients treated with the real-time tumor tracking. Toxicity was low.
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Introduction 
Tumors of the lung are prone to motion which affects both intra- and inter-fractional radia-
tion delivery. This motion is largely caused by respiratory breathing. The degree of motion 
tends to be small in tumors located in the upper lobe and those attached to the chest wall, but 
larger in small peripheral tumors. These tumors often move more than 1 cm and sometimes 
as much as 3 cm during deep in- or expiration (1). To accommodate this range of motion, 
conventional radiotherapy has typically used safety margins in the order of 1-2 cm. These 
margins decrease the risk of missing the tumor, at the cost of irradiating a larger volume 
of healthy lung tissue. The necessity for large safety margins in conventional radiotherapy 
limits dose escalation. This is the main reason for the poor local tumor control (LC) rates in 
patients with early-stage NSCLC (51%) (2). 
High local control rates exceeding 90% have been reported for early-stage NSCLC patients 
treated with stereotactic radiotherapy (SRT) (3-5). This technique not only precisely targets 
and delivers radiation, but also reduces the effects of tumor motion. These characteristics 
of SRT allow reduction of safety margins surrounding the tumor volume. Consequently, 
treatment volumes are reduced and treatment doses can be escalated. The following methods 
have been applied to reduce the impact of respiratory tumor motion: 1) Patient-specifi c 
treatment volumes based on tumor motion observed during planning CT scans , 2) forced 
shallow breathing with abdominal compression, 3) breath-hold methods, 4) respiratory gat-
ing methods and 5) real-time tumor tracking (6). 
Real time tumor tracking corrects for tumor motion during respiration by repositioning the 
radiation beam to the position of the moving tumor. This technique is applied by the Syn-
chrony Respiratory Tracking System (RTS). The tracking system is part of the CyberKnife 
Robotic Radiosurgery treatment unit (Accuray Inc. Sunnyvale, USA) and requires the inser-
tion of radio-opaque markers. The Synchrony RTS targets the tumor by moving the linear 
accelerator by means of a robotic manipulator. Synchrony RTS was implemented in 2004. 
Few clinical results have been published for the treatment of lung cancer with real-time 
tumor tracking using the Synchrony RTS (7, 8). In each of these studies no more than 30 
NSCLC patients were included. Clinical results of patients treated prior to 2004 were re-
ported however these patients were not treated with real-time tumor tracking (9, 10). These 
studies used the breath-holding technique to account for tumor motion.
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The purpose of this study is to report and compare the results of 70 patients treated with real-
time tumor tracking, of whom 59 were treated with 60 Gy and 11 were treated with 45 Gy in 
three fractions. In addition, we will also address the question whether marker placement is 
feasible in patients with poor lung function.
Methods 
Patients were eligible for treatment if they had inoperable T1-T2N0M0 NSCLC, refused 
surgery and if there was a peripheral tumor location. A peripheral tumor was located ≥2 cm 
from the trachea and main bronchus on the CT-scan. Patients were considered inoperable in 
the presence of severe co-morbidity or when tumors were deemed irresectable. Pathologi-
cal confi rmation was highly recommended. Comorbidity was registered using the Charlson 
comorbidity index and the cumulative illness ranking score (11, 12). 
Prior to treatment, markers were placed in or near the tumor. Depending on the risk of pneu-
mothorax, markers were placed via the percutaneous intra- or extra-pulmonary approach or 
via the vascular approach (13, 14). Briefl y, percutaneous marker placement required fl uo-
roscopy or CT-guidance to place platinum markers into or near the tumor (intrapulmonary 
approach) or in the thoracic wall against the ribs (extrapulmonary approach). The vascular 
approach involved the insertion of embolisation coils into small subsegmental end branches 
of the pulmonary artery near the tumor using a transcatheter. Ideally a minimum of 3 markers 
have been implanted to allow for correction of translational and rotational target motion. 
A planning CT-scan of the chest with slice thickness and spacing of 1.5-2 mm was obtained 
4-7 days after marker placement. The gross tumor volume (GTV) defi ned as visible tumor, was 
contoured using lung window. We added a 5 mm margin to the GTV to account for microscopic 
tumor extension and residual inaccuracy of the Synchrony RTS (~1.5 mm) (15, 16). Patients 
were initially treated with 3 fractions of 12 Gy (n=1) or 15 Gy (n=10). The dose was escalated 
to 3 fractions of 20 Gy (n=59). The dose was prescribed to the 70-85% isodose line, covering 
at least 95% of the PTV. The maximum dose was defi ned by the 100% isodose line.
Treatment consisted of approximately 130 non-coplanar beams using one or two circular 
collimator cones sizes (20-60 mm). Median treatment time was 1h40min (range 47min-
3h30min) at a dose rate of 400 MU/min. Treatment planning was carried out with the On 
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Target treatment planning system, version 3.4.1, Accuray Inc., Sunnyvale, CA. The equiva-
lent path-length method was used for correction of tissue inhomogeneity. Dose constraints 
are listed in table 1. 
Table 1. Dosis constraints for critical structures
Organ Volume Dose (Gy)
Spinal Cord Any point 8 Gy per fraction
Esophagus Any point 7 Gy per fraction
Trachea and main bronchus Any point 10 Gy per fraction
Plexus Brachialis Any point 8 Gy per fraction
Liver Any point 20 Gy per fraction
Lung <31% of the total volume 4.5 Gy per fraction
All patients were treated with real-time tumor tracking. A detailed description of the Cy-
berKnife Synchrony RTS has been reported previously (13-15). Briefl y, motion of red light-
emitting diodes attached to the patients’ chest was registered and correlated to the location 
of implanted markers, as determined by a series of orthogonal x-ray images taken during 
respiration. The correlation model directed the robot arm and targeted the tumor with the 
6 MV radiation beam. During treatment the correlation model was validated and updated. 
The fi rst clinical examination was performed three weeks after SRT. Clinical visits and CT-
scans were performed 2-3, 6, 9, 12, 18, 24 and 30 months thereafter. Toxicity was evaluated 
using the Common Terminology Criteria for Adverse Events version 3.0 (17). Toxicity was 
acute if it occurred within 4 months and late if it occurred thereafter.
The primary objective was to evaluate the effi cacy of radiotherapy in terms of local control. 
Local control was calculated from the fi rst day of treatment until diagnosis of a local recur-
rence. Patients without a local recurrence were censored on the last day of contact. In the 
absence of pathological confi rmation of malignancy, local recurrence was defi ned as a 20% 
increased CT-tumor dimension compared to the previous CT-scan. In addition a correspond-
ing avid lesion on the PET-scan was required. Overall survival was measured from the start of 
radiotherapy until death of any cause. Cause-specifi c survival was measured from the start of 
radiotherapy until death of lung cancer. Patients alive at the last date of contact were censored. 
Local control and overall survival were estimated by the Kaplan-Meier method, and 95% 
confi dence intervals (95% CIs) were constructed. Cox regression analysis was used to 
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evaluate the prognostic value of patient and tumor characteristics on survival endpoints. 
Differences between subgroups were illustrated and compared with Kaplan-Meier curves 
and the log-rank test. All P-values are two-sided. A signifi cance level α = 0.05 was used.
Results
Seventy patients with stage I NSCLC were treated using real-time tumor tracking from 
August 2005- October 2007. Patient and tumor characteristics are summarized in table 2. 
Patient comorbidity scores were high (table 2). Sixty-fi ve patients (93%) were inoperable 
and 5 patients (7%) refused surgery. Thirty-nine patients had T1-tumors and 31 had T2-
tumors. Histology was obtained in thirty-six (51%) of the seventy lung tumors. All thirty-
four patients (49%) without histology had PET scans, as did 93% of the study population. 
In 63 patients activity on the PET scan was limited to the primary tumor site. The other two 
patients had a synchronous tumor located in the breast and head & neck region. 
Table 2. Patient and tumor characteristics
Median age (years, range) 76 (54-90)
Charlson comorbidity score
 >4
 3-4
 1-2
 0
5 (7%)
31 (44%)
32 (46%)
2 (3%)
Cumulative Illness score
 >6
 5-6
 0-4
23 (33%)
16 (23%)
31 (44%)
Histology
 Large cell carcinoma
 Squamous cell carcinoma
 Adenocarcinoma
 Undifferentiated carcinoma
No biopsy or inconclusive biopsy
36 (51%)
16 (44%)
11 (31%)
7 (19%)
2 (6%)
34 (49%)
Forced expiratory volume in 1 second (FEV1) (L)
 Median (Range) 1.38 (0.81-3.81)
Gross tumor volume (cc)
 Median (Range) 11.8 (0.7-176.5)
Planning target volume (cc)
 Median (Range)
 
35.0 (4.9-254.0)
Tumor diameter (cm)
 Median (Range)
 
2.7 (1.0-10.0)
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Two-hundred-twenty-fi ve markers were placed. One-hundred forty-three markers (43%) 
were placed with the vascular approach in 43 patients. Seventy-two markers (32%) were 
placed with the intrapulmonal approach in 25 patients and ten markers (4%) were placed us-
ing the extra-pulmonal approach in two patients. A median of 3 markers have been placed per 
patient (range 1-5). Grade 3 toxicity occurred in two patients (3%). One had a pneumothorax 
requiring a chest drain; another had cardiac arrhythmia after intravascular coil placement 
and required a pacemaker. Grade 2 toxicity occurred in one patient who was observed at the 
hospital for a pneumothorax but required no chest drain. Six patients had grade 1 toxicity 
consisting of minor dyspnea (n=1), pneumothorax without clinical symptoms (n=2) and self-
limiting pulmonary haemorrhage (n=3). 
The estimated local control rate was 96% (95% CI=84-99%) at 2-years for 59 patients treated 
with 60 Gy compared to 78% (95% CI=37-94%) for 11 patients treated with 45 Gy (fi gure 
1A; p=0.197). After treatment with 60 Gy, T1 tumors had 100% local control at 2-years 
compared to 89% (95% CI=76-100%) for T2 tumors (fi gure 1B; p=0.085). Characteristics of 
patients with a local recurrence (n=4) are stated in table 3. All local recurrences were seen 
in patients with T2 tumors. No signifi cant difference in local control was seen for patients 
with or without pathology. Three patients had regional (4%) and seven patients had distant 
metastases (10%). Five patients had both distant and regional recurrences (7%). 
The estimated overall survival was 83% (95% CI=71-90%) at one year and 62% (95% 
CI=45-75%) at two years. Patient-, tumor- and treatment characteristics and presence/
absence of pathology, had no infl uence on survival (fi gure 1C; p=0.64). Nineteen patients 
died during follow-up; six died of metastatic NSCLC (32%), 13 died of intercurrent disease 
(68%). Causes of intercurrent death are summarized in table 4. The cause-specifi c survival 
was 94% at one year and 86% at two years.
No grade 4 or 5 toxicity occurred after treatment. Acute Grade 1-2 toxicity occurred in 
32 patients, consisting mostly of fatigue, dyspnoe and cough. One patient had acute grade 
3 toxicity, requiring morfi ne for severe thoracic pain. Late grade 3 toxicity was observed 
in 7 patients (10%). Three patients had radiation pneumonitis treated with antibiotics and 
corticosteroids. Four patients had thoracic pain requiring morfi ne. They all had a tumor near 
the chestwall. A rib fracture was found in one of these patients. 
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Figure 1(A). Local control rates of patients treated with 45 Gy and 60 Gy (p=0.197). 
Figure 1(B). Local control rates of patients with T1 and T2 tumors treated with 60 Gy (p=0.085). 
Figure 1(C). Overall survival of patients with and without pathology treated with 60 Gy (p=0.64).
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Discussion 
In our study, estimated local control of 59 NSCLC patients treated with 60 Gy in 3 fractions 
was 96% at two years. Estimated two-year local control was 78% in 11 patients treated 
with 45 Gy in 3 fractions. Clinical results after treatment with real-time tumor tracking are 
sparse (7, 8). The two studies available included patients with NSCLC as well as pulmonary 
metastases. The fi rst study treated 51 patients with 60 Gy in 3 fractions, only 26 patients 
had NSCLC. After a median follow-up of 11 months the crude local control for the NSCLC 
patients was 85% (7). The second study treated patients with 45-60 Gy in 3 fractions and 
included 15 stage I NSCLC patients. Crude local control was 100% after a median follow-up 
of 12 months (8). This local control rate appears superior to ours, but the sample size was 
Table 3. Characteristics of patients with a local recurrence
Patient Total dose (Gy) Pathology Gross tumor 
volume (cc)
Planning target volume 
(cc)
Months to local 
relapse 
1 45 Large cell 10 37 14
2 45 SCC 177 254 15
3 60 No PA 15 39 6 
4 60 SCC 26 61 10
Table 4. Characteristics of patients who died during follow-up
Sex (Age) Charlson score Cummulative Illness 
Ranking
Cause of death
Male (78) 4 6 Sudden death
Male (75) 3 4 Sudden death
Female (83) 0 3 Myocardial infarction
Female (73) 1 2 Myocardial infarction
Male (85) 1 7 General deterioration
Male (90) 4 4 General deterioration
Male (69) 7 16 Cardiac decompensation after dialysis
Male (77) 7 14 Haemorrhage from a leiomyoma of 
the oesofagus
Male (80) 3 7 Cardiac decompensation
Female (61) 3 9 Haemorrhage of the digestive tract
Male (76) 3 3 Cerebrovascular bleeding
Male (83) 3 4 Cerebrovascular infarction
Male (76) 3 6 Unknown
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small. In addition only small lung tumors were treated (median GTV of 8 cc; range 1-14 
cc). In our study the median GTV was 11.8 cc but the largest tumor was 176.5 cc. All the 
T1-tumors in our study also had 100% local control. 
Similar local control rates are reported by studies using patient-specifi c treatment volumes 
and abdominal compression. Crude local control of 97% at 12 months was reported in 206 
patients treated using patient specifi c treatment volumes (18). Local control rates after treat-
ment with abdominal compression are also comparable to our study. At 3 years, crude local 
control was 80-98% after treatment with 45 Gy in 3-4 fractions (3, 19). Variation in local 
control may be related to the proportion of T2-tumors treated. Local control was 98% after 
treating mainly T1-tumors, and 80% after treating mainly T2-tumors. 
Clinical results are limited after breath-hold or respiratory gated treatment. In addition, study 
sizes are small. Despite this, similar local control rates were reported after breath-holding. 
Crude local control at a median follow-up of 13 months was 94% in 35 stage I NSCLC 
patients treated with 60 Gy in ten fractions (4). Ng et al. treated 20 patients with 45-54 
Gy in 3-4 fractions; only fi ve patients were treated using the deep inspiration breath hold 
technique. Local control was 94% at 2 years for the whole group (5). Despite these results, 
breath holding may be poorly tolerated by patients with mediocre lung function and active 
patient and therapist participation is often required (20). 
Local control rates after respiratory gated treatment are lower in studies using lower doses 
but comparable when a similar dose is delivered. Local control was 73% at two years and 
57% at three years in 41 NSCLC patients treated with 40-48 Gy in 4 fractions (21). Local 
control was signifi cantly higher with greater radiation doses (p=0.0059) and in T1 tumors 
compared with T2 tumors (p=0.0059). In another study, 27 of 59 lung tumors were treated 
with respiratory gating; the respiratory cycle was too irregular in 9 patients and tumor mo-
tion was <10 mm in 23 patients. Local control was 83% at 2 years after treatment with a 
single fraction of ≥30 Gy, compared with 52% after treatment with ≤30 Gy (22). This study 
demonstrates a benefi t of higher radiation dose on local control. It also demonstrates that not 
all patients are suitable for respiratory gating despite the indication. 
In our study a somewhat lower local control rate (89% at 2 years) was seen in T2-tumors, 
even when treated with 60 Gy in 3 fractions (p=0.085). The number of local recurrences are 
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however too small (n=4) to make conclusions about the infl uence of dose and tumor stage on 
local control. Despite this our results do not contradict previously published results. 
The studies above all used methods to regulate tumor motion, aimed at reducing irradiation 
of healthy tissue and escalating the dose to the target while maintaining toxicity at an accept-
able level. To safely reduce treatment volume it is not suffi cient to consider intra-fractional 
tumor motion alone. Shifts in the base-line position of the tumor between fractions forms a 
larger source of error (23). Even when margins are not reduced, these variations can cause 
the tumor to be situated outside the treatment fi eld. In-room imaging prior to each treatment 
fraction can minimize this error if the imaging technique allows direct visualization of the 
tumor, or visualization of surrogate markers implanted near the tumor. CyberKnife uses 
the surrogate marker technique and localizes the tumor trajectory prior and during each 
treatment fraction. 
Despite the achievement of excellent local control, the overall survival was 62% at two 
years. Others have reported two-year overall survival rates of 64-83% (4, 18). The cause-
specifi c survival rate of 86% at two years, was similar to that reported by others (78% at 2 
years) (5, 21). Presumably patient selection plays a role in the variation of overall survival. 
In our study ≥90% of patients were medically inoperable and 56% of patients had a cumula-
tive illness ranking score of ≥5. Given the high comorbidity, the 11 intercurrent deaths were 
not completely unexpected. The cause of intercurrent death is unknown in three patients. 
These patients were all free of treatment related symptoms and had no evidence of a local 
recurrence on the CT-scan made 1-2 months prior to their death. All three patients had a 
history of severe pulmonary, cardiac or cerebrovascular disease. 
Late grade 3 toxicity occurred in 7 patients (10%) after a median follow-up of 15 months. 
Others report late toxicity in 3-8% of patients (8, 18, 24). With increasing follow-up our inci-
dence of toxicity may rise. Despite this, toxicity seems comparable to that reported by others 
with 12 months of follow-up (8, 18). Diffi culties to distinguish between treatment-related 
symptoms and the natural course of COPD may cause variation in reported toxicity. Two of 
our patients with radiation pneumonitis had a history of COPD and the CT-scans showed only 
slight ground-glass effects. The symptoms may have resulted from a COPD exacerbation. 
On the other hand SRT may render patients more susceptible to COPD exacerbations. The 
incidence of pain syndromes and rib fractures was similar to that reported previously (18). 
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The use of implanted markers required for real-time tumor tracking is a major concern 
due to the risk of pneumothorax after percutaneous intrapulmonal placement. The risk is 
approximately 17-53% with 4-40% requiring treatment (25, 26). Only one patient in this 
series required treatment after percutaneous intrapulmonal marker placement. The incidence 
of pneumothorax was low due to the available alternative methods of marker placement 
(vascular and extra-pulmonary approach). The vascular approach was complicated by grade 
3 toxicity in one patient. This patient, with a pre-existent conduction abnormality, required 
pacemaker implantation for a complete third degree atrioventricular block. 
Another limitation of our study is the absence of pathologic confi rmation of malignancy in 
49% of the patient population. This limitation is not uncommon in radiotherapy trials treating 
patients with poor pulmonary function as the risk of trans-thoracic biopsies are frequently too 
high (18, 19). According to the malignancy prediction model of Swensen et al. the risk for 
malignancy is very high in our older patient population of whom the majority have smoked 
(27). The additional requirement of PET scanning added to the prediction model of Swensen 
et al. further minimizes the risk of treating a benign lesion (28). The specifi city of PET to 
differentiate between benign and malignant nodules is 70%-95% (29). Although the PET 
scan can not give certainty that all the lesions treated in this study were malignant, it was 
ensuring to fi nd similar local control and overall survival rates in patients with and without 
pathological confi rmation of disease.
Conclusion
Excellent local control of 96% at 2 years was achieved for NSCLC patients treated with 60 
Gy using real-time tumor tracking. These results were obtained while adapting a tight 5 mm 
margin and allowing patients to breath freely. The cause-specifi c survival rate of 86% at 2 
years was comparable to that reported by other SRT studies. Treatment related toxicity was 
low as was toxicity after marker placement. As various marker placement techniques were 
available even patients with a poor lung function could be treated safely.
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Abstract
As the incidence of stage I non-small cell lung cancer (NSCLC) increases among octogenar-
ians and only selected patients are surgical candidates, an alternative treatment is necessary. 
This manuscript evaluates the overall survival, local tumor control rate, and treatment 
related toxicity after stereotactic body radiotherapy (SBRT) in 38 octogenarians with stage 
I NSCLC. Treatment consisted of 45 Gy (n=4) or 60 Gy (n=25) in 3 fractions for patients 
with peripheral tumors. A risk adaptive schedule of 45-60 Gy in 3-6 fractions was used for 
central (n=7) or large peripheral tumors (n=2). An overall survival rate of 65% at one year 
and 44% at two years was achieved in octogenarians after SBRT. The local tumor control rate 
was excellent (100% at two years) and no grade 4 or 5 treatment related toxicity occurred. 
Despite the high incidence of comorbidity in these octogenarians (Charlson score ≥5 in 16% 
of patients), an approach that merely provides supportive care cannot always be justifi ed. 
SBRT offers octogenarians with stage I NSCLC a good treatment alternative. 
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Introduction 
As life expectancy increases, more octogenarians will present with stage I non-small lung 
cancer (NSCLC). The treatment of these patients with potentially resectable lung cancer is 
challenging. Although treatment decisions are often based on prospective randomized tri-
als, elderly patients are highly underrepresented in these trials due to their age or stringent 
inclusion criteria. As a result these trials cannot guide treatment decisions in elderly patients 
(1, 2). Other concerns are patient frailty and the assumption that life-expectancy is limited. 
Treatment is therefore often primarily aimed at avoiding side effects, and preserving quality 
of life while curation is of secondary concern. 
The trend for more conservative management of NSCLC in elderly (3, 4) may deprive elderly 
patients of both quantity and quality of life. A nihilistic approach in elderly with NSCLC 
cannot be justifi ed as more than 50% of patients die due to their cancer (5). In addition the 
projected life expectancy of octogenarians is on average >7 years (6, 7). Although 5-year 
survival rates after surgery in octogenarians are encouraging (34-57%) (8-11), careful patient 
selection is essential and postoperative morbidity and mortality are not negligible (10, 12, 
13). An alternative to surgery currently used to treat patients with inoperable stage I NSCLC 
is stereotactic body radiotherapy (SBRT). 
SBRT precisely targets and delivers radiation to the tumor even when the tumor moves 
during respiration. The methods used to account for respiratory tumor motion include 1) 
patient specifi c treatment volumes based on tumor motion, 2) forced shallow breathing with 
abdominal compression, 3) breath-holding during irradiation, 4) respiratory-gated radio-
therapy and 5) real-time tumor tracking. As a result of the precise targeting, stereotactic 
radiotherapy can deliver a higher dose per fraction and thus higher biological effective doses 
than conventional radiotherapy. SBRT in the general population achieves local tumor control 
rates similar to those after surgery (92%) and the overall survival rates range from 26-83% 
at 2-5 years (14-18). 
In this study we determined the overall survival, the rate of death due to cancer progression 
and intercurrent disease, and the local tumor control rate after SBRT in octogenarians with 
stage I NSCLC. SBRT was delivered using real-time tumor tracking. Complications after 
marker placement and treatment-related toxicity were also evaluated.
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Methods 
A review of our prospective database identifi ed 38 octogenarians with cT1-2N0M0 NSCLC 
who were treated with SBRT from August 2005 to July 2008. Pathologic confi rmation of 
malignancy was obtained in 22/38 patients (58%) and a PET-scan was obtained in 34/38 
patients (89%). Those patients without pathology had a growing lesion on the computer 
tomography (CT) scan and an avid lesion on the positron emission tomography (PET) scan. 
Hilar or mediastinal nodes with a short axis <1 cm on CT and no abnormal hilar or mediasti-
nal uptake on PET were considered N0. Activity on the PET-scan was limited to the primary 
tumor in all patients. Comorbidity was scored using the Charlson comorbidity index (table 
1) and the cumulative illness ranking score (19, 20). Patient and tumor characteristics are 
listed in table 2. 
Table 1. The Charlson comorbidity scale
Comorbidity Points
Myocardial infarction 1
Congestive heart failure 1
Peripheral vascular disease 1
Dementia 1
Chronic pulmonary disease 1
Connective tissue disease 1
Ulcer disease 1
Mild liver disease 1
Diabetes (without complications) 1
Diabetes with end-organ damage 2
Hemiplegia 2
Moderate or severe renal disease 2
Second solid tumor (non-metastatic) 2
Leukemia 2
Lymphoma, multipele myeloma 2
Moderate or severe liver disease 3
Second metastatic solid tumor 6
Acquired immunodefi ciency syndrome 6
Patients were treated with SBRT using the CyberKnife. CyberKnife accurately targets and 
radiates the tumor using the synchrony respiratory tracking system (RTS). This system 
requires insertion of radio-opaque markers near the tumor, and enables the CyberKnife to 
compensate for tumor motion. It does this by continuously repositioning the radiation beam 
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to the position of the moving tumor. Details on marker placement and the RTS have been 
published previously (21, 22). Briefl y, markers were placed via the vascular, percutaneous 
intrapulmonary or percutaneous extrapulmonary approach. Seventy-four markers were 
placed via the vascular approach in 22 patients, 46 markers were placed via the percutaneous 
intrapulmonary approach in 15 patients and 5 markers were placed via the percutaneous 
extrapulmonary approach in one patient. On average 3 markers (range 1-5 markers) were 
placed per patient to allow for correction of translational and rotational motion. A planning 
CT-scan was obtained 4-7 days after marker placement. The gross tumor volume (GTV) was 
delineated using the lung window setting. The planning target volume (PTV) was obtained 
by adding a 5 mm margin to the GTV. This margin accounts for microscopic tumor extension 
and inaccuracy of the synchrony RTS (23, 24). 
Table 2. Patient and tumor characteristics
Median age (range) 82 (80-90) 
Medically inoperable
Refused surgery
34 (89%)
4 (11%)
Charlson comorbidity score
 0
 1-2
 3-4
 >5
1 (3%)
14 (37%)
17 (45%)
6 (16%)
Cumulative Illness score
 0-4
 5-6
 >7
9 (24%)
9 (24%)
20 (53%)
T1
T2
12 (32%)
26 (68%)
Peripheral tumor location
Central tumor location
32 (84%)
6 (16%)
Histology
 Large Cell carcinoma
 Squamous cell carcinoma
 Adenocarcinoma
 Undifferentiated carcinoma
No biopsy or inconclusive biopsy
22 (58%) 
8 (36%)
7 (32%)
4 (18%)
4 (18%)
16 (42%)
Forced expiratory volume in 1 second (FEV1) (L)
 Median (Range) 1.57 (0.79-3.08)
Gross tumor volume (cc)
 Median (Range) 18.2 (2.4-376.5)
Planning target volume (cc)
 Median (Range)
 
46.2 (14.8-609.5)
Tumor diameter (cm)
 Median (Range)
 
3.5 (1.6-10.5)
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In the treatment room, the location of the implanted markers was determined by a series of 
orthogonal x-ray images taken during respiration. At the same time, motion of red light-
emitting diodes on the patients’ chest was registered and correlated to the location of the 
implanted markers. The resulting correspondence model was used to move the robot arm 
and direct the radiation beam at the tumor. Treatment of peripheral tumors (located ≥2 cm 
from the trachea and main bronchus) initially consisted of 45 Gy in 3 fractions (n=4) but 
was escalated to 60 Gy in 3 fractions (n=25). The dose was escalated to 60 Gy in 3 fractions 
as it was demonstrated that this was a safe and effective dose (25, 26). Two large peripheral 
tumors could not be treated with this dose due to normal tissue constraints. Instead they 
received 50-60 Gy in 5 fractions. Central tumors were treated with 6 x 8 Gy if they were lo-
cated near the oesophagus. Otherwise they received 5 x 9-12 Gy (n=4). Dose was prescribed 
to the 78-87% isodose line, covering at least 95% of the PTV. Maximum dose was defi ned 
by the 100% isodose line. The equivalent pathlength algorithm was used to correct for tissue 
inhomogeneity. The dose constraints to organs at risk are given in table 3. 
Table 3. Dose constraints for the organs at risk
Organ Volume Schedule 3 x 20 Gy
Dose per frac. (Gy)
Schedule 6 x 8 Gy 
Dose per frac. (Gy)
Schedule 5 x 12 Gy
Dose per frac. (Gy)
Spinal Cord Any point 8 4.5 5.5 
Esophagus Any point 7 6 7 
Heart Any point 12 8 10 
Trachea and main bronchus Any point 10 8 10 
Plexus brachialis Any point 8 5 6 
Lung V20 (EQD2) <31% <31% <31%
Clinical visits and CT-scans were performed every 3 months during the fi rst year, and every 
6 months thereafter. A local recurrence was defi ned as a 20% increased tumor diameter 
compared to the diameter on the previous CT-scan. In addition, a corresponding avid lesion 
was required on the PET-scan. Local tumor control was calculated from the day of treatment 
until a local recurrence was diagnosed or until the last day of contact for patients without a 
recurrence. Overall survival was measured from the fi rst day of radiotherapy until death from 
any cause. Patients alive on the last date of contact were censored. Toxicity was evaluated 
using the Common Terminology Criteria for Adverse Events version 3.0 (27). 
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Statistical considerations 
Kaplan-Meier analysis was used to estimate the local tumor control rate and overall survival 
and to determine 95% confi dence intervals (CIs). The rate of death due to cancer progression 
and intercurrent disease were also determined using competing risk analysis. The prognostic 
value of tumor stage on overall survival was determined using the logrank test. The infl uence 
of tumor stage on death due to cancer progression and death due to intercurrent disease 
were also evaluated. The cox-regression analysis was used to evaluate the impact of the 
Charlson comorbidity score on intercurrent death. P values <0.05 were considered statisti-
cally signifi cant. 
Results
The overall survival was 65% (95% CI = 47-78%) at one year and 44% (95% CI = 27-61%) 
at two years. Death due to cancer progression was 18% and death due to intercurrent disease 
was 38% at two years (fi gure 1). Surviving patients had a median follow-up of 23 months. 
The two-year overall survival was 81% for T1 and 29% for T2 tumors (p<0.01, fi gure 2). 
No statistically signifi cant difference was seen in the overall survival at two-years for tumor 
location (50% for peripheral versus 17% for central tumors, p=0.07) or treatment dose (52% 
for patients treated with 3 fractions of 20 Gy versus 31% for patients treated with a lower 
dose, p=0.53). The median survival was 20 months. Death due to disease progression was 
10% in T1 tumors and 21% in T2 tumors at two years (p=0.06). At two years, death due 
to intercurrent disease was 8% in T1 tumors and 51% in T2 tumors (p=0.02). The mean 
Charlson comorbidity score (CCS) and cumulative illness ranking score (CIRS) were not 
signifi cantly different for patients with T1 or T2 tumors (CCS = 2 for T1 vs 3 for T2, p=0.28; 
CIRS = 6 for T1 vs 7 for T2, p=0.32). Table 4 summarizes the cause of death for patients 
with T1 and T2 tumors and the time of death. Twenty-one patients died; seven died due 
to disease progression and fourteen died due to intercurrent disease. The cause of death 
was unknown in one patient with a sudden death. Of the fourteen patients with intercurrent 
death, ten patients died in the fi rst year after treatment. In the patients who died of a cardiac 
cause (n=5), general deterioration (n=3) or due to a sudden death (n=1), the median of the 
maximum heart dose was 1.2 Gy (range: 0.1-4.4 Gy). The patients who died of pneumonia 
(n=1), general deterioration (n=3) or a sudden death (n=1) all had a V20 (EQD2) well below 
the constraint of 31% (median 15%). The Charlson comorbidity score had no signifi cant 
infl uence on intercurrent death. 
Noelle bw.indd   57 29-03-11   17:05
58 ■ Chapter 4
C
um
ul
at
iv
e 
pe
rc
en
ta
ge
months
0 6 12 18 24
0
25
50
75
100
OS
DIS
INT
Figure 1. Overall survival (OS), death due to cancer progression (DIS) and death due to intercurrent 
disease (INT).
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Figure 2. Overall survival for T1 and T2 tumors treated with SBRT (p=0.01).
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Local tumor control was 100% at one and two years. Complications after marker placement 
occurred in 2 patients (5%). One had a pneumothorax after intrapulmonary marker place-
ment and required a thorax drain. The other patient required a pacemaker after vascular coil 
placement. This patient had pre-existent atrioventricular conduction abnormalities. 
Table 4. Cause of death
Number of deaths Time till death (months) Tumor category
Disease progression 7
Lung metastases 2 18, 20 T1 =1 , T2 = 1
Leptomeningeal metastases 1 2 T2
Brain metastases 1 32 T2
Brain & liver metastases 1 4 T2
Lymphangitis carcinomatosa 1 9 T2
Carcinomatous pleuritis 1 15 T2
Intercurrent disease 14
Abdominal aneurysm 1 7 T2
Sepsis (toe infection) 1 1 T2
Cerebral haemorrhage 1 2 T2
Haemoptysis* 1 13 T2
Cardiac death 5 2, 3, 8, 17, 30 T1 = 1, T2 = 4 
COPD/pneumonia 1 9 T2
General deterioration 3 9, 10, 12 T1 = 1, T2 = 2
Sudden death/unknown 1 22 T2
* Haemoptysis as a result of anticoagulant therapy
Treatment-related grade ≥4 toxicity did not occur. Two patients had acute grade 3 toxicity 
(5%). One had self-limiting chest pain 3-8 weeks after treatment and temporarily required 
pain medication. The other patient was admitted to the hospital for chest pain and dyspnoe. 
The pain was attributed to an exacerbation of chronic obstructive pulmonary disease (COPD) 
and resolved with antibiotics and prednisone. Dyspnoe remained severe. Although late toxic-
ity could not be evaluated in all patients due to limited follow-up, 32 patients were followed 
≥6 months and 22 patients were followed ≥12 months. Of these patients, fi ve (16%) had 
late grade 3 or higher toxicity including: dyspnoe related to severe COPD (n=2), thoracic 
pain (n=2) and grade 3 radiation pneumonitis six months after treatment (n=1). The patient 
with acute grade 3 dyspnoe related to COPD also had late grade 3 dyspnoe related to severe 
COPD. The patients presenting with thoracic pain (at 9 and 12 months) had mild or no pain 
at the following out-patient visit. 
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Discussion
An overall survival of 65% at one year and 44% at two years were achieved after SBRT in 
octogenarians with stage I NSCLC, while the rate of cancer progression was 18% at two 
years. Local tumor control was excellent (100%) and toxicity was low after marker place-
ment (5%) and radiation treatment (5% acute and 16% late grade 3 toxicity). The overall 
survival rate was signifi cantly higher in T1 than T2 tumors. Although the rate of death due 
to disease progression was higher in T2 tumors than in T1 tumors (21% versus 10%), this 
difference was not statistically signifi cant. It should be noted that this difference may not be 
statistically signifi cant as a result of the small number of patients that died of progressive 
disease. 
While the survival rate after SBRT in our study was merely 44% at two years, fi ve-year 
survival rates of 34-79% are reported after surgery in octogenarians with stage I NSCLC (8-
10). The largest surgical study included 196 patients with stage I NSCLC. Overall survival 
for stage 1A disease was 90% at one year and 48% at fi ve years. For stage 1B disease it 
was 83% at one year and 39% at fi ve years (9). Surgical series emphasize careful selec-
tion of physically fi t octogenarians (10, 28-30). Overall survival after surgery was worse in 
octogenarians with ≥2 comorbidities than for those with less comorbidity (31). The extent 
of selection in some surgical series is high: curative resections in octogenarians with stage 
I-II NSCLC accounted for merely 4-6% of the total number of curative lung resections 
performed at two centers (8, 10). In our study comorbidity was severe. Fourteen patients 
(16%) had a Charlson comorbidity score ≥5. This score is associated with an increased risk 
of mortality (19, 32). Mortality due to intercurrent disease occurred in fourteen patients (T1 
N=2, T2 N=12). As the mean comorbidity scores were not signifi cantly different for patients 
with T1 and T2 tumors, this does not explain the higher rate of intercurrent death in patients 
with T2 tumors. Despite this, the higher intercurrent death rate in patients with T2 tumors 
may well be coincidental. Death due to an abdominal aneurysm, sepsis from a toe infection 
and cerebral hemorrhage could well have happened in either patients with T1 or T2 tumors 
and are not related to the tumor stage or treatment. The other intercurrent deaths in patients 
with T1 and T2 tumors (cardiac death n= 5, pneumonia n=1, general deterioration n=3, and 
sudden death n=1) were also not the result of treatment related toxicity. The patients that died 
due to cardiac disease, general deterioration and an unknown cause all had treatment plans in 
which the maximum dose to the heart was <5 Gy (median 1.2 Gy, range 0.1-4.4 Gy). As the 
maximum dose to the heart in these patients was well below the dose constraint, these deaths 
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were not the result of cardiac toxicity related to SBRT. The V20 (EQD2) was also well below 
the constraint for the patients that died of pneumonia, general deterioration or sudden death. 
Besides the high incidence of comorbidity, another factor that may contribute to the lower 
survival in our study is the absence of surgical staging. Patients treated with SBRT may have 
been under-staged. This may lower overall survival after SBRT. Lastly, some surgical series 
have excluded postoperative deaths from their overall survival analysis in order to evaluate 
factors that infl uence long-term survival (8, 9). By doing this, overall survival after surgery 
appears higher. 
Although the survival in our study is merely 44% at 2 years (median survival of 20 months), 
the estimated survival of untreated early stage NSCLC is poor (5, 13, 33). Knowledge of 
the natural course of untreated stage I NSCLC in octogenarians is limited. For patients aged 
54-84, the median survival was 14 months in untreated patients versus 46 months following 
surgery (5, 33). In a second study, the median survival for a general population with untreated 
stage I-II NSCLC was 13 months (overall survival of 58% at one year and 8% at two years) 
(7). Survival rates are poor after a best-supportive care approach. Therefore best supportive 
care should be replaced by active treatment even in octogenarians. Many octogenarians will 
be unsuitable for surgery due to the high probability of severe comorbidity (29, 31, 34). In 
addition, the physiologically reduced lung function in octogenarians can lead to signifi cant 
morbidity after surgery. Prior to the wide-spread availability of SBRT, patients with stage I 
NSCLC were treated with dose escalated conventional radiotherapy in an attempt to improve 
outcomes compared with conventional radiotherapy. Radiation doses up to 94.5 Gy in 42 
fractions could be safely given to patients with small-volume lung tumors and were associ-
ated with better treatment outcomes (35, 36). Patients with stage I-III NSCLC had an overall 
survival of 44% at two years and 28% at fi ve years after treatment with >92 Gy (36). A 
direct comparison with our SBRT study is however hampered as this study included patients 
younger than 80 years with a performance status of 0-2. An advantage of SBRT over dose 
escalated conventional radiotherapy is that SBRT allows for hypofractionated radiotherapy, 
thereby shortening the overall treatment time while high doses can be delivered due to the 
accurate targeting of the tumor. 
At our institute, SBRT in 38 octogenarians achieved excellent local tumor control. Similar 
local tumor control has been reported by the largest multi-institutional SBRT study including 
245 Japanese early-stage NSCLC patients. Patients were 35-92 years old, the majority had a 
World Health Organisation (WHO) performance score of 0-1 and 65% were inoperable due 
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to COPD, other chronic illnesses or advanced age. At 5 years, local control was 92% and 
overall survival was 47% (90% for operable patients) (14). Although Japanese and western 
patients differ, these results suggest that SBRT is a good alternative to surgery, and that 
survival rates for operable patients may be similar. The role of SBRT in operable early stage 
NSCLC patients is currently examined by a randomized trial in the Netherlands (the ROSEL 
trial) and by an international randomized trial (the STARS- trial). 
Treatment related morbidity and mortality are also important in making treatment decisions 
for octogenarians with stage I NSCLC. Grade 3 treatment-related morbidity occurred in 6 
patients (one within 4 months, four thereafter, and one persisting after 4 months). Although 
the incidence of late toxicity may increase with longer follow-up, 32 patients were followed 
>6 months and 22 patients were followed >12 months. All toxicity was self-limiting and 
treatment-related mortality did not occur despite severe comorbidity in our patients before 
treatment. 
Morbidity and mortality has been drastically reduced after surgery owing to strict pre- and 
postoperative measures and advances in surgical techniques including the introduction of 
less invasive lung preserving operations. Despite these advances, 11-30% of octogenarians 
treated with surgery had major morbidity (mainly cardiopulmonary) (8, 13). Mortality rates 
in octogenarians have been reduced from 30% in the sixties (37) to current rates just below 
2% for limited pulmonary resections (38). Despite this, the risk of mortality still increases 
with each decade of life (33, 38, 39) and reported rates of mortality in octogenarians still 
vary enormously (0-15%) (8, 10, 12, 13, 38). Variation in these mortality rates are caused by 
small study sizes, differences in hospital treatment volumes and the extent of lung surgery. 
High volume academic centers generally do better than community based centers (39) and 
the mortality risk in the general population after a pneumonectomy is higher than after a 
wedge resection (7.2% versus 0.6%) (34). Although limited resections are preferable due 
to the lower complication risk, not all octogenarians will have a tumor suitable for limited 
resection as tumors may be >2.5 cm or located centrally in the lung. And even after limited 
resections using video-assisted thoracoscopy, mortality rates remained 10% in patients with 
an impaired performance status (33). As such, treatment with stereotactic radiotherapy may 
be a safer alternative for octogenarians with early-stage NSCLC. 
Although toxicity is low and hospital admission is not needed, a disadvantage of treatment 
using the CyberKnife is the necessity of markers for tumor tracking. In a signifi cant portion 
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of patients the risk of a pneumothorax after intrapulmonary marker placement was too high. 
In these cases, bronchoscopic or intravascular marker placement provides a solution. Our 
complication rate after marker placement was acceptably low (5%) even when compared to 
complications in younger populations (16-28%) (40, 41). Treatment was also tolerated well 
by octogenarians despite treatment times of approximately 90 minutes. Improved CyberKnife 
technology allows treatment in less than 60 minutes. Low toxicity and excellent local tumor 
control are obtained with CyberKnife treatment. Similar results could be obtained with the 
various other SBRT methods mentioned in the introduction. 
A drawback of our study is the absence of pathological confi rmation of malignancy in 58% 
of patients while it is confi rmed in all patients treated with surgery. The absence of pathology 
is a common problem in radiotherapy trials as the risk of trans-thoracic biopsies is often too 
high due to poor pulmonary function (16, 42). Despite this, the risk of malignancy in elderly 
patients who have smoked is very high according to Swensen’s malignancy prediction model 
(43). The risk of treating a benign lesion is further reduced by the PET-scan, which has a 
specifi city of 70-95% to differentiate between malignant and benign lesions (44). Although 
our study is non-randomized and has potentially introduced a selection bias of relatively 
healthy octogenarians, the high rate of comorbidity suggests that even octogenarians with 
multiple comorbidities can be safely treated with SBRT.
Conclusion 
Stereotactic radiotherapy in octogenarians with stage I NSCLC achieved an overall survival 
rate of 65% at one year and 44% at two years, and the rate of cancer progression was 18% 
at two years. The local tumor control rate was excellent (100%) and the marker placement 
complication rate (5%) and treatment related toxicity were low (5% acute grade 3 toxicity 
and 16% late grade 3 toxicity).
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Abstract
Purpose 
To determine the impact of stereotactic radiotherapy (SRT) on the quality of life (QoL) of 
inoperable patients with early-stage non-small cell lung cancer (NSCLC). Overall survival, 
local tumor control and toxicity were also evaluated in this prospective study. 
Methods 
From January 2006 to February 2008 quality of life, overall survival and local tumor control 
were assessed in 39 patients with pathologically confi rmed T1-2N0M0 NSCLC. These 
patients were treated with SRT. The European Organization for Research and Treatment 
of Cancer Quality of Life Questionnaire (EORTC QLQ-C30) and the lung cancer specifi c 
questionnaire (QLQ-LC13) were used to investigate changes in QoL. Assessments were 
done before treatment, at 3 weeks, and 2, 4, 6, 9 and 12 months after treatment until death 
or progressive disease. Toxicity was evaluated using the common terminology criteria for 
adverse events version 3.0. 
Results
Emotional functioning improved signifi cantly after treatment. Other functional scores, 
QLQ-C30 and QLQ-LC13 lung symptoms (as dyspnea and coughing) showed no signifi cant 
changes. Overall two-year survival was 62%. After a median follow up of 17 months one 
patient had a local recurrence (3%). No grade 4 or 5 treatment related toxicity occurred. 
Grade 3 toxicity consisted of thoracic pain and occurred in one patient within four months of 
treatment while it occurred thereafter in two patients.
Conclusion
Quality of life was maintained and emotional functioning improved signifi cantly after ste-
reotactic radiotherapy for stage I NSCLC while survival was acceptable, local tumor control 
was high and toxicity was low. 
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Introduction
Stereotactic radiotherapy (SRT) is an important treatment modality in patients with inop-
erable stage I non-small cell lung cancer (NSCLC). Although surgery is the treatment of 
choice, many patients are medically inoperable due to smoking-related comorbidity. For 
these patients stereotactic radiotherapy is a good alternative treatment, achieving local tu-
mor control rates above 90% (1-3) and 5-year overall survival rates of 47% (4). An equally 
important aim of any cancer treatment is to maintain or improve the patients’ quality of life. 
Given the high level of comorbidity in many patients with NSCLC and the limited overall 
survival, it is of great interest to assess the impact of treatment on the patients’ quality of 
life. Although quality of life has been evaluated after conventional radiotherapy in patients 
with NSCLC, reports of quality of life after stereotactic radiotherapy are sparse. The aim of 
this prospective study is to assess the impact of stereotactic radiotherapy on the quality of 
life of inoperable patients with NSCLC using the European Organization for Research and 
Treatment of Cancer (EORTC) quality of life questionnaire QLQ-C30 and the lung cancer 
specifi c supplementary questionnaire QLQ-LC13. In addition the overall survival, local 
tumor control rate, and treatment related toxicity were evaluated. 
Methods
Patients 
From January 2006 to February 2008, 43 patients with pathologically confi rmed T1-2N0M0 
NSCLC entered our prospective phase II trial and were treated with real-time tumor tracking 
using the CyberKnife. Patients were eligible for the trial if they refused surgery or had an 
inoperable tumor. The trial was approved by the Medical Ethical Committee of the Erasmus 
MC and was in accordance with the Declaration of Helsinki. Four patients were excluded 
from quality of life analysis; two due to a lacking pre-treatment assessment, one due to 
progressive disease shortly after the fi rst follow-up assessment at 3 weeks, and one patient 
declined to participate in the quality of life study after inclusion. Pathological confi rmation 
of malignancy was obtained in all patients. Diagnostic staging included a CT-scan in all pa-
tients and a PET-scan in all but four patients. Comorbidity was registered using the Charlson 
comorbidity index and the cumulative illness ranking score (5, 6). Patient characteristics are 
listed in table 1. One patient had a T2 tumor at the time of inclusion but a T3 tumor at the 
time of treatment. This patient is included in this analysis.
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Table 1. Patient and tumor characteristics
Median age (years, range) 77 (55-87)
Medically inoperable
Refused surgery
33 (85%)
6 (15%)
Charlson comorbidity index
 0-2
 3-4
 >4
20 (51%)
13 (33%)
6 (15%)
Median cumulative illness ranking (range) 6 (2-16)
Incidence of COPD 22 (56%)
Tumor location
 Peripheral
 Central
33 (85%)
6 (15%)
T-classifi cation
 T1
 T2
 T3
17 (44%) 
21 (54%) 
1 (3%)
Histology
 Squamous cell carcinoma
 Large cell carcinoma
 Adenocarcinoma
 Other
14 (36%)
13 (33%)
8 (21%)
4 (10%)
Planning target volume (PTV) median (range) 46 cc (7-609 cc)
Treatment 
All patients were treated with real-time tumor tracking using the synchrony respiratory 
tracking system of the CyberKnife. This system requires the insertion of radio-opaque mark-
ers and enables the radiation beam to reposition to the location of the moving tumor. Details 
on the marker placement techniques and the synchrony tumor tracking system have been 
published previously (7-9). 
Markers were placed via the vascular approach in 24 patients, the percutaneous transthoracic 
approach in 14 patients and the bronchoscopic approach in 1 patient. On average 3 mark-
ers (range 1-5 markers) were placed per patient to allow for correction of translational and 
rotational motion. Four to seven days after marker placement a planning CT-scan with slice 
thickness and spacing of 1.5-2 mm was obtained. The visible tumor (gross tumor volume, 
GTV) was delineated using the lung window setting. We added a 5 mm margin to the GTV 
to account for microscopic tumor extension and residual inaccuracy of the synchrony RTS 
(approximately 1.5 mm) (9-11).
In the treatment room, motion of red light-emitting diodes attached to the patients’ chest was 
registered. This motion was correlated to the location of the implanted markers, determined 
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by a series of orthogonal x-ray images taken during the respiratory cycle. This correspon-
dence model was used to direct the radiation beam at the tumor. During treatment the cor-
relation model was validated and updated. 
Treatment consisted of 60 Gy in 3 fractions for 30 patients. A risk-adaptive treatment 
schedule consisting of 48-50 Gy in 5-6 fractions was used to treat six patients with central 
tumors and one patient with a large T2 tumor. Two patients were treated with 45 Gy in 3 
fractions by choice of the treating physician. Treatment dose was prescribed to the 78-87% 
isodose line, covering at least 95% of the PTV. The maximum dose was defi ned by the 100% 
isodose line. Treatment was carried out with 2 circular collimator cone sizes (20-60mm) and 
approximately 130 non-coplanar beams. Treatment planning was done with the On Target 
treatment planning system, version 3.4.1, Accuray Inc., Sunnyvale, CA. Tissue inhomogene-
ity was corrected for using the equivalent path-length method. Dose constraints can be found 
in table 2. None of the patients were treated with chemotherapy prior to treatment or in 
adjuvant setting.
Table 2. Dose constraints for critical structures
Organ Volume Dose (Gy)
Spinal Cord Any point 6 Gy per fraction
Esophagus Any point 7 Gy per fraction
Trachea and main bronchus Any point 10 Gy per fraction
Plexus Brachialis Any point 8 Gy per fraction
Lung <31% of the total volume 4.5 Gy per fraction
Quality of Life Instruments 
Quality of life assessments were performed before treatment, at 3 weeks and at 2, 4, 6, 9 
and 12 months. As the peak incidence of acute toxicity (including radiation pneumonitis) 
occurs within 6 -12 months of treatment and rarely thereafter (12), QoL was assessed over 12 
months, thus allowing the infl uence of acute toxicity on the QoL to be examined. Patients with 
evidence of progressive disease were excluded from further analysis to prevent bias caused 
by disease progression or by the treatment of progressive disease. Quality of life was evalu-
ated by means of the European Organization for Research and Treatment of Cancer quality 
of life core questionnaire (EORTC QLQ-C30) and the supplementary lung cancer specifi c 
module, the QLQ-LC13. The QLQ-C30 (version 3.0) is a 30-item questionnaire composed 
of fi ve functional scales (physical, role, emotional, cognitive and social functioning), three 
symptom scales (fatigue, pain and nausea and vomiting), a global health status/quality of life 
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scale and six single items. The single items assess additional symptoms commonly reported 
by cancer patients including dyspnea, constipation, diarrhea, sleep disturbance, loss of ap-
petite and the fi nancial impact of the disease and treatment. All of the scales and single items 
have a score in the range of 0 to 100. A high score for the functional and QoL scale represents 
a high level of functioning/high quality of life, whereas a high symptom score represents a 
high level of symptoms. The QLQ-C30 questionnaire has been validated in a sample of lung 
cancer patients in 13 countries (13). The lung cancer module is designed for patients with 
varying disease stages treated with chemotherapy and/or radiotherapy. It comprises of 13 
questions assessing lung cancer associated symptoms (cough, hemoptoe, dyspnea and site 
specifi c pain), treatment related side effects (sore mouth, dysphagia, peripheral neuropathy 
and hair loss) and pain medication. The scoring approach is identical to that of the single 
items in the QLQ-C30 questionnaire. Both questionnaires have been translated and validated 
for use in a Dutch population. 
Follow-up and toxicity scoring
The fi rst clinical examination was performed three weeks after SRT. Clinical follow-up was 
performed every three months and a CT-scan was performed 2, 4, 6, 9 and 12 months after 
treatment. Toxicity was scored at each out-patient visit by the patients’ physician using the 
common terminology criteria for adverse events version 3.0 (CTCAEv3.0) (14). Toxicity 
was acute if it occurred within 4 months and late if it occurred thereafter.
Statistics
Changes in the mean QoL and symptom scores over time were evaluated with a multilevel 
mixed-effects linear regression model using ‘xtmixed’ in Stata version 10.1. The method 
of restricted maximum likelihood was used to estimate the parameters of the model. Wald 
tests were used for testing main effects of time. Overall survival was measured from the 
start of radiotherapy until death of any cause. Patients still alive at the date of last contact 
were censored. Local tumor control was calculated from the fi rst day of treatment until the 
diagnosis of a local recurrence. Patients without a local recurrence were censored on the 
last day of contact. In the absence of biopsy-confi rmed viable carcinoma, local recurrence 
was defi ned as a 20% increased longest tumor dimension on the CT-scan compared to the 
previous CT-scan. In addition a corresponding avid lesion on the PET-scan was required. All 
P-values were two-sided, and a signifi cance level = 0.05 was used. 
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Results
Compliance of Quality of Life Assessments 
Quality of life was assessed in thirty-nine patients. Compliance was 90% at 3 weeks (35 
forms of 39 patients still alive without progression), 95% at 2 months, (35/37), 95% at four 
months (35/37), 100% at 6 months (33/33), 96% at nine months (27/28) and 95% at 12 
months (18/19). 
Quality of Life and baseline symptoms 
Global health status and respiratory symptoms did not deteriorate after CyberKnife treatment 
as the changes in mean score over time were small and not signifi cant. The size of the 
PTV and the tumor location (central vs peripheral) did not signifi cantly infl uence changes in 
global health status and respiratory symptoms. The only signifi cant change observed in the 
quality of life scores at every time interval was an improvement of the emotional functioning 
score; p=0.02). None of the other functional scores or symptom scores changed signifi cantly. 
Changes in the QLQ-C30 mean global health status and functional scores are depicted in 
fi gure 1. Changes in QLQ-LC13 symptom scores are depicted in fi gure 2. The QLQ-LC13 
score for dyspnea increased by 6 points at 6 months. At 12 months dyspnea decreased almost 
to baseline. These changes were not signifi cant. The QLQ-LC 13 score for coughing also did 
not change over time. 
The most frequently reported baseline respiratory symptoms were dyspnoe in 90% of patients 
and coughing in 67% of patients. Fatigue was the most frequent general symptom affecting 
87% of patients. Symptoms at baseline are listed in table 3. 
Overall survival and local tumor control 
Overall survival was 75% (95% CI=58-86%) at one year and 62% (95% CI=42-77%) at 
two years. Twelve patients died; six died of metastatic disease and six patients died of in-
tercurrent disease. Causes of intercurrent death were: cardiac failure (n=3), mortality during 
surgery for an aneurysm of the abdominal aorta (n=1), sudden death of unknown cause 
(n=1) and general deterioration in an 85-year-old patient (n=1). Local tumor control was 
97% (95% CI=78-99%) at one and two years. One patient had a local recurrence and eleven 
patients had distant metastases. Of the eleven patients with distant metastases, fi ve patients 
had mediastinal lymph nodes. The median follow-up was 17 months (6-31 months). 
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Figure 1. Change in mean global health and functional scores during follow-up
Noelle bw.indd   76 29-03-11   17:05
 Chapter 5 ■ 77
Figure 2. Change in mean QLQ-LC13 symptom score (dyspnea, coughing, chest pain, pain in the arm, 
and fatigue score) during follow-up.
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Table 3. Symptoms at baseline
Patients with symptoms (%) Mean score (SD)
Symptoms (QLQ-LC13)
Dyspnea 90 36 (26)
Fatigue 85 39 (29)
Coughing 67 35 (31)
Pain 51 23 (30)
Insomnia 46 24 (31)
Pain arm/shoulder 39 23 (33)
Pain elsewhere 39 23 (35)
Appetite loss 31 13 (21)
Pain chest wall 26 14 (25)
Hemoptysis 8 3 (9)
Functioning scales (QLQ-C30)
Global health status NA 62 (21)
Physical functioning NA 62 (24)
Role functioning NA 64 (35)
Emotional functioning NA 69 (27)
Cognitive functioning NA 79 (26)
Social functioning NA 78 (30)
SD: standard deviation  NA: not applicable
QLQ-LC 13: Lung cancer-specifi c quality of life questionnaire
QLQ-C30: Quality of Life Questionnaire C30
Toxicity 
No grade 4 or 5 toxicity was observed. Twelve patients had no acute side effects at all. The 
most common grade 1 and 2 toxicities were fatigue and dyspnea. Acute grade 3 toxicity 
occurred in one patient (2.6%) who required morfi ne for thoracic pain. Late grade 3 toxicity 
occurred in two patients (5.1%) with thoracic pain. None of the patients developed grade ≥3 
radiation pneumonitis (table 4). 
Table 4. Treatment-related toxicity
Grade No. of patients with indicated score (% of total)
Acute grade 4 or 5 0
Acute grade 3 1 (3)
No Acute toxicity 12 (31)
Late grade 4 or 5 0
Late grade 3 2 (5)
No late toxicity 16 (41)
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Discussion
Quality of life and respiratory symptoms did not deteriorate after stereotactic radiotherapy 
and emotional functioning was signifi cantly improved. The two year survival rate of 62% 
and the local tumor control rate of 97% were achieved without detrimental effects on the 
quality of life. The low rate of treatment related toxicity observed during follow-up is in line 
with the fi nding that quality of life did not deteriorate. 
Studies reporting the impact of conventional high dose radiotherapy on quality of life in stage 
I NSCLC patients are sparse. One study reported the outcome of 46 stage I NSCLC patients 
who were treated with 70 Gy in 2 Gy fractions (15). Although the global quality of life did 
not deteriorate, dyspnea and fatigue gradually worsened, emotional functioning did not im-
prove, and the overall survival was 39% at two years as compared with 62% in our study. The 
worsening of dyspnea and fatigue was attributed to the natural progressive nature of COPD 
and the late sequelae of conventional radiotherapy. A worsening of respiratory symptoms was 
not observed in our study while the incidence of COPD (56% in our study vs 48%) and the 
duration of follow-up were similar (17 months in our study vs 19 months). Although the dura-
tion of follow-up was slightly shorter in our study, it was long enough to observe radiation 
pneumonitis, which is likely to worsen respiratory symptoms. Functional and symptom scores 
at baseline also could not account for the difference in outcome as these scores were slightly 
worse in our study. Although the incidence of toxicity is not mentioned by Langendijk, the low 
incidence of toxicity after stereotactic radiotherapy may be the reason why symptom scores did 
not increase in our study. The risk of late toxicity is small (2-8%) after treating patients with 
stereotactic radiotherapy as treatment volumes are generally small (4, 12, 16). On the other 
hand, the risk of toxicity after stereotactic irradiation of central tumors is not negligible (17) 
and may infl uence the patient’s quality of life. In our study no severe toxicity was observed 
in central tumors (n=6). The reason for this may be the use of the risk-adaptive treatment 
schedule for central tumors; on the other hand, the number of central tumors was small. 
Publications concerning the infl uence of stereotactic radiotherapy on quality of life in cancer 
patients are also sparse. The impact of stereotactic radiotherapy on the quality of life has been 
reported for primary and metastatic liver tumors. A prospective phase I/II study examined the 
impact of stereotactic treatment on the quality of life in 28 patients with metastatic liver tumors 
treated mostly with three fractions of 12.5 Gy. Three quality of life instruments were used, 
among which the EORTC QLQ-C30 (18). High local tumor control was achieved after SRT 
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and no detrimental changes were observed on the quality of life. These results are similar to 
those seen in our study. Perhaps the highly localized and non-invasive nature of stereotactic ra-
diotherapy is the reason that treatment was well-tolerated. The increased emotional functioning 
in our study may be the result of the excellent local tumor control achieved after SRT, giving 
patients a brighter outlook on their future, while they do not have treatment related side effects.
Although surgery is the treatment of choice in patients with stage I NSCLC and overall 
5 year survival rates are as high as 67% (19), the infl uence of surgery on quality of life is 
still controversial. Several studies have reported only a temporary decline in the quality of 
life after surgical treatment, with symptom and functional scores returning to baseline at 3 
months after treatment (20, 21), while others state that recovery is not complete (22-25). A 
prospective study including 159 NSCLC patients, found that physical functioning, dyspnea 
and pain remained signifi cantly impaired even up to 24 months after surgery. Patients who 
underwent a pneumonectomy had signifi cantly worse quality of life than those who had a 
limited resection (22). Although an irreversible detrimental effect of surgery on the quality of 
life is not consistently reported, the effect of extensive lung parenchyma resection on long-
term quality of life seems less controversial. After pneumonectomy, functional and symptom 
scales did not return to baseline during the 12 months of follow-up, while after lobectomy 
and wedge-resections, functional and symptom scores returned to baseline after 3 months, 
indicating a good recovery (23). Although pneumonectomy holds a high risk of worsening 
a patient’s quality of life, this procedure is necessary when tumors are located centrally in 
the lung. In our study the number of patients with central tumors was low (n=6, 15%) and as 
reported by Timmerman, the risk of toxicity in these patients is higher than in peripheral tu-
mors (17). The patients with central tumors in our study did not have a large and statistically 
signifi cant change in quality of life after treatment but the number of patients with central 
tumors is too small to detect moderate but perhaps clinically relevant changes in quality of 
life. The impact of the size of the planning target volume on the quality of life is also of 
great interest as the treatment of larger volumes may increase the risk of worsening quality 
of life, as is the case for pneumonectomies. Although no large change in quality of life was 
observed, the small sample size is once again a limitation to detect moderate but perhaps 
clinically relevant changes. In our study no deterioration is seen in quality of life after SRT, 
even though the majority of patients were inoperable due to comorbidity. In comparison, 
even after lobectomy there was at least a temporary decline in quality of life. Survival after 
stereotactic radiotherapy in our study was 62% at 2 years while it was as high as 67% at fi ve 
years after surgery (19). The difference in survival may be explained by the different rates 
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of comorbidity. As the patient populations differ, a randomized trial is evidently necessary 
to compare the effect of surgery and stereotactic radiotherapy on treatment related changes 
in quality of life and survival. 
Although statistical analysis can identify differences in quality of life scores before and 
after treatment, interpretation of these changes and their impact on clinical decision making 
are important, yet complex. Defi ning the minimum clinically important difference in mean 
scores is challenging. Treatment may give improvement in one dimension of quality of life 
at the cost of another dimension. As such, determining the clinical relevance of changes in 
mean scores after treatment requires consideration of the different dimensions of quality of 
life but also endpoints such as overall survival and local tumor control. The defi nition of 
a clinically relevant difference is subjective as both patients and clinicians are individuals 
with subjective values. A small change in quality of life may be of great value to a severely 
disabled patient while it is of little value to a relatively healthy patient. King et al. considered 
a difference in the mean global quality of life score of 15 points as a relatively large clinical 
difference and a change in score of 5 points as a relatively small clinical difference (26). 
This guideline is supported by Osoba et al. who evaluated the impact of changes in EORTC-
QLQ mean scores on the way the treated patients experienced these changes (27). Using a 
subjective signifi cance questionnaire, this study was able to detect changes in mean EORTC-
QLQ scores that were perceived as important by patients. When patients indicated moderate 
changes in perceived quality of life, the mean EORTC-QLQ score changed by 10-20 points. 
For large perceived changes, the mean EORTC-QLQ score changed by >20 points. As can be 
seen in fi gure 1, none of the mean EORTC-QLQ scores in our study changed by ≥10 points 
for more than one of the six time points except emotional functioning. Although our study 
is non-randomized and small changes in quality of life scores may not be detectable in our 
study due to population size (n=39), the lack of >10 point changes suggests that there are no 
moderate or large perceived changes in quality of life scores. 
Conclusions
The level of quality of life prior to treatment was maintained after treatment with stereotactic 
radiotherapy and emotional functioning improved signifi cantly. While maintaining the qual-
ity of life, stereotactic radiotherapy achieved acceptable overall survival (62% at 2 years), 
local tumor control (97% at 2 years) and low treatment related toxicity. 
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Abstract
Purpose
To provide a prescription dose for Monte Carlo (MC) treatment planning in patients with 
non-small-cell lung cancer according to tumor size and location.
Methods
Fifty-three stereotactic radiotherapy plans designed using the equivalent path-length (EPL) 
algorithm were recalculated using MC. Plans were compared by the minimum dose to 95% 
of the PTV (D95), the heterogeneity index (HI) and the mean dose to organs at risk (OARs). 
Based on changes in D95, the prescription dose was converted from EPL to MC. Based on 
changes in the HI, we examined the feasibility of MC dose prescription to plans recalculated 
but not re-optimized with MC. 
Results
The MC fraction dose for peripheral tumors is 16-18 Gy depending on tumor size. For 
central tumors the MC dose was reduced less than for peripheral tumors. The HI decreased 
on average by 4-9% in peripheral tumors and by 3-5% in central tumors. The mean dose to 
OARs was lower for MC than EPL, and correlated strongly (R2 =0.98-0.99). 
Conclusion
For the conversion from EPL to MC we recommend a separate prescription dose according 
to tumor size. MC optimization is not required if a HI ≥70% is accepted. Dose constraints to 
OARs can be easily converted due to the high EPL-MC correlation. 
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Introduction
Stereotactic radiotherapy (SRT) accurately targets and delivers radiation to early stage 
non-small cell lung cancer (NSCLC), achieving local tumor control rates above 90% (1, 2). 
Despite these promising results, large deviations in planned and delivered dose are found 
when treatment planning is based on dose calculation using simple heterogeneity correc-
tion algorithms (3-6). Due to the sigmoidal dependence of tumor control and normal tissue 
toxicity on radiation dose, uncertainties in dose calculation along the steep gradient of the 
dose-response curve may lower the probability of tumor control or increase toxicity (7).
Simple heterogeneity correction algorithms, such as the equivalent pathlength algorithm 
(EPL), consistently underestimate the penumbra width in low density regions and overes-
timate dose to the planning target volume (PTV) (4, 8). These errors occur because the 
simple algorithms merely account for decreased attenuation of the primary photon beam in 
low density lung tissue, while increased electron range is not accounted for. Monte Carlo 
dose calculation (MC) on the other hand explicitly accounts for these effects. It is the most 
accurate dose calculation algorithm currently available (8-10) as it transports photons and 
electrons individually through the patient volume. MC can now be used in clinical practice 
as calculation times have been reduced by high performance computers and variance reduc-
tion techniques.
The clinical introduction of MC however requires an adjustment of the currently used EPL 
prescription dose. Without this adjustment, the risk of normal tissue complications will 
increase as EPL systematically overestimates the dose delivered to the PTV while MC does 
not. Furthermore, it is not possible to simply convert the prescription dose from EPL to MC. 
This is because the magnitude of dose difference between EPL and MC are highly dependent 
on several factors including beam arrangements, fi eld size, beam energy, and tumor size and 
location (7). A previous study compared EPL and MC plans for tomotherapy treatment (4). 
The aim of this study is to 1) compare dose distributions calculated with EPL and MC for 
CyberKnife treatment, 2) propose a MC prescription dose for NSCLC patients according 
to tumor size and location and 3) examine the feasibility of MC prescription to EPL plans 
recalculated with MC, but not re-optimized with MC. 
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Methods
Treatment plan selection
The treatment plans used in this study were derived from early-stage NSCLC patients 
previously treated with SRT using the CyberKnife (Accuray Inc., Sunnyvale, CA) (2, 11). 
Treatment plans were selected to include a range of tumor sizes and locations (central or 
peripheral) (12) . Fifty-three treatment plans were evaluated. Tumor characteristics are listed 
in table 1.
Table 1. Tumor characteristics
Peripheral Tumors Central Tumors Total group
Total 33 20 53
Tumor Size
 <3 cm 
 3-5 cm 
 >5 cm
 >7 cm 
12 (36%)
12 (36%)
8 (24%)
1 (3%)
-
8 (40%)
6 (30%)
6 (30%)
12 (23%)
20 (38%)
14 (26%)
7 (13%)
Tumor diameter (cm) 
 Median
 Range
3.8 
0.9 - 8.0 
5.4 
3.3 - 12.2 
4.3 
0.9 - 12.2 
Gross tumor volume (cm3)
 Median
 Range
13.5 
0.7 - 83.3 
47.7 
4.9 - 370 
19.6 
0.7-370 
Planning target volume (cm3)
 Median
 Range
37 
4.9 - 149 
97.4 
19.1 - 528 
52.6 
4.9 - 528 
Treatment planning
An exhale treatment planning CT-scan was made of the entire thorax, with slice thickness 
and spacing of 1.5-2 mm. The gross tumor volume (GTV) was delineated using lung window 
setting. The PTV = GTV + 5 mm (2). Organs at risk (OARs) were contoured and defi ned 
according to the RTOG 0236 protocol (12). The lungs and spinal cord were contoured in 
all treatment plans while the heart, oesophagus, bronchus and ribs were contoured if they 
received ≥4 Gy per fraction. Ribs were contoured in bone window setting if any part of the 
rib received ≥4 Gy per fraction. Treatment consisted of 3 x 20 Gy in peripheral tumors, 6 x 8 
Gy in central tumors located near the oesophagus and 5 x 12 Gy in all other central tumors. 
Dose was prescribed to the isodose line covering at least 95% of the PTV (usually the 80% 
isodose line; range 75-87%). The maximum dose was defi ned by the 100% isodose line. 
Dose constraints to OARs have been described previously (13). Treatment plans were gener-
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ated using the On Target treatment planning system (version 3.4.1, Accuray Inc., Sunnyvale, 
CA.). The plans were optimized using EPL dose calculation. This process has been described 
previously (14). 
Recalculation of treatment plans in Multiplan 
For the purpose of this study, all treatment plans were transferred from On Target to the Mul-
tiplan treatment planning system (version 2.2.0, Accuray Inc, Sunnyvale, CA). Multiplan 
has implemented both EPL and MC dose calculation. The MC dose calculation algorithm 
has been validated at our institute (15). It is based on MC particle transport and incorporates 
ideas from previously developed algorithms (16-19). The treatment plans in Multiplan were 
fi rst recalculated with EPL, and then with MC. This was done to eliminate subtle differences 
between the On Target and Multiplan treatment planning systems. A high-resolution grid 
(256^2) was used for the EPL and MC calculations and the variance in MC calculation 
was set to 2%. MC computation time was approximately 5-10 minutes. We verifi ed that a 
variance of 2% yielded similar dose volume parameters as a variance of 1%. As the plan 
recalculated with MC was the same as the EPL plan, the number of beams and monitor units 
were the same. 
Comparison of EPL and MC re-calculated plans (first aim) 
We compared the EPL and MC re-calculated plans by: 1) the minimum dose to 95% of the 
PTV (D95), 2) the minimum dose to 99% of the PTV (D99), 3) the mean PTV dose, 4) the 
percentage of PTV receiving the prescribed dose, and 5) the PTV heterogeneity index (HI), 
defi ned as the ratio of D95 and D1 (the minimum dose to 1% of the PTV). Although the HI 
is usually defi ned as the ratio of D95 and the maximum dose, we chose D95/D1 because 
the maximum dose is a less reliable dose metric in MC dose calculation (due to statistical 
uncertainties) (20). Differences in dose parameters were reported as the percentage of dose 
difference from the EPL plan. Treatment plans were evaluated separately according to a 
central or peripheral tumor location but also according to tumor size (<3 cm, 3-5 cm and 
>5 cm). Tumor size and location were taken into account as these parameters are expected 
to infl uence the magnitude of dose difference between EPL and MC calculated plans. The 
tumor size groups were chosen in accordance to the size criteria used by the 7th TNM clas-
sifi cation for T1, T2a and T2b/T3 tumors (21). The mean and maximum doses to OARs were 
also compared. 
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Monte Carlo Dose prescription 
The second aim of our study was to propose a MC prescription dose for NSCLC patients 
according to tumor size and location. The EPL prescription dose was converted to a MC 
prescription dose based on the median difference in D95 in EPL and MC recalculated plans. 
In agreement to recommendations by the AAPM task force, we prescribed the MC prescrip-
tion dose to an isodose surface rather than to a single point (20). 
We prescribed the MC prescription dose to the plans re-calculated with MC. Plans were not 
optimized with MC as the generation of MC optimized plans requires three time consuming 
steps in Multiplan. These three steps include: 1) the selection of beams and beam weights by 
designing a treatment plan using EPL dose calculation 2) re-calculation of the dose distribu-
tion for this beam-set using the MC algorithm and 3) optimization of these beam-weights 
using MC dose calculation. The MC prescription dose was prescribed to the isodose surface 
that enclosed exactly 95% of the PTV (rather than prescribing dose to a predetermined 
isodose surface that enclosed at least 95% of the PTV). This means that the PTV coverage 
with the prescribed dose is per defi nition 95% in each treatment plan, while the isodose 
surface varies between treatment plans. Our method of dose prescription will impact the 
dose heterogeneity of the PTV. Therefore, for the third aim of our study, the HI was used to 
assess the feasibility of prescribing dose to a variable isodose surface in MC re-calculated 
(but not re-optimized) plans. We compared the HI in plans recalculated with MC and EPL 
for peripheral and central tumors. As the current EPL prescription dose for central tumors 
has not yet been validated, we assessed the feasibility of MC dose prescription for peripheral 
tumors only. Dose prescription to MC re-calculated plans was considered feasible if the HI 
in MC re-calculated plans was ≥70%. 
The consequence of prescribing the MC dose to plans recalculated with MC (but not re-
optimized with MC) was also assessed for peripheral tumors only. We determined the differ-
ence in dose parameters between 1) the plans prescribed with MC and 2) the plans prescribed 
with EPL and re-calculated with MC (fi gure 1).
Statistics
The Kruskal-Wallis test was used to determine whether changes in EPL and MC calculated 
dose parameters were signifi cantly different for the tumor size groups (<3 cm, 3-5 cm and >5 
cm). The Spearman rank correlation test and linear regression analysis were used to evaluate 
the infl uence of multiple factors on the change in D95 between EPL and MC calculated plans. 
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The factors included: 1) GTV, 2) tumor diameter, 3) peripheral or central tumor location, 4) 
the minimal distance between the tumor and soft tissue and 5) the cone size used during treat-
ment. A paired t-test was used to test the null-hypothesis that the average dose parameters 
were the same in plans prescribed with MC and plans prescribed with EPL and re-calculated 
with MC. All p-values are two-sided, and a signifi cance level α = 0.05 was used. 
Results
Peripheral Tumors
The D95, D99 and mean dose to the PTV and GTV were reduced when EPL plans were 
recalculated with MC (table 2). The reduction in PTV D95, D99 and mean dose was signifi -
cantly different for the three tumor size groups (Kruskal-Wallis test, p <0.01). The median 
reduction in MC dose was greatest for small tumors but the inter-patient variation was also 
greatest for patients with small tumors (fi gure 2). 
“On Target” EPL plan
Transfer to “Multiplan”
MC re-calculated plan
EPL re-calculated plan
Determine MC prescription dose §
MC prescribed plan
Prescribe MC prescription dose 
without optimizing 
MC re-calculated plan
*
#
Figure 1. All treatment plans were transferred from “On Target” to the “Multiplan” treatment planning 
system. In Multiplan, treatment plans were fi rst recalculated with EPL, and then with MC in order to 
eliminate subtle differences between the treatment planning systems. First aim: we compared EPL and 
MC re-calculated plans (*). Second aim: the MC prescription dose was determined (§), based on the 
comparison of D95 in plans recalculated with EPL and MC. Third aim: we determined the impact of MC 
dose prescription by comparing 1) the MC prescribed plan with 2) the EPL prescribed plan re-calculated 
with MC (= MC recalculated plan) (#).
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Table 2. Reduction in D95, D99 and mean dose when EPL plans are recalculated with MC. The median 
dose reduction, standard deviation and range are provided.
 % Reduction in D95 (peripheral) % Reduction in D95 (central)
PTV
< 3 cm 21 ± 8 (6-33) -
3-5 cm 17 ± 6 (6-30) 12 ± 5 (7-22)
> 5 cm 10 ± 4 (7-18) 8 ± 4 (3-18)
GTV
< 3 cm 14 ± 6 (2-25) --
3-5 cm 12 ± 6 (4-25) 8 ± 3 (6-16)
> 5 cm 8 ± 2 (4-10) 7 ± 3 (3-14)
% Reduction in D99 (peripheral) % Reduction in D99 (central)
PTV
< 3 cm 21 ± 8 (7-35) -
3-5 cm 18 ± 7 (5-33) 10 ± 7 (3-25)
> 5 cm 11 ± 4 (6-18) 8 ± 5 (1-19)
GTV
< 3 cm 15 ± 7 (1-27) -
3-5 cm 13 ± 7 (4-25) 9 ± 3 (6-15)
> 5 cm 8 ± 2 (6-10) 6 ± 4 (0-13)
% Reduction in Dmean (peripheral) % Reduction in Dmean (central)
PTV
< 3 cm 17 ± 7 (3-28) -
3-5 cm 13 ± 5 (6-23) 12 ± 3 (7-16)
> 5 cm 8 ± 3 (5-13) 8 ± 4 (3-15)
GTV
< 3 cm 14 ± 5 (2-22) -
3-5 cm 11 ± 4 (5-19) 10 ± 3 (6-14)
> 5 cm 7 ± 2 (4-11) 7 ± 3 (3-14)
PTV= planning target volume, GTV= gross tumor volume.
Dmean= mean dose
D95= dose to 95% of the target volume
D99= dose to 99% of the target volume
The percentage of PTV receiving 60 Gy signifi cantly decreased from on average 97% (range: 
90-100%) to 42% (3-81%) when EPL plans were recalculated with MC (p <0.01). Although 
our EPL dose prescription protocol requires at least 95% of the PTV to receive the prescribed 
dose, PTV coverage was merely 90% in one EPL plan. In this plan, a concession was made 
to the PTV coverage in order to spare a rib. The heterogeneity index decreased by on average 
9% in tumors <3 cm, 8% in tumors of 3-5 cm, and 4% in tumors > 5 cm when EPL plans 
were recalculated with MC. 
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Central Tumors
The D95, D99 and mean dose to the PTV and GTV were reduced when EPL plans were 
recalculated with MC, but the reduction was less than for peripheral tumors (table 2). The 
percentage of PTV receiving the prescribed dose signifi cantly decreased from on average 
93% (range: 70-99%) to 52% (range: 32-88%) when EPL plans were recalculated with MC 
(p <0.01). A concession was made to the PTV coverage in seven EPL plans in order to 
spare OARs. The heterogeneity index decreased on average by 3-5% when EPL plans were 
recalculated with MC. 
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Figure 2. Ratio of MC and EPL calculated dose (PTV D95, D99 and mean dose) for peripheral and 
central tumors. Bold diamonds represent tumors <3 cm, open triangles represent tumors of 3-5 cm and 
bold triangles represent tumors >5 cm.
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Organs at Risk
The mean and maximum dose to OARs calculated with EPL and MC correlated strongly 
(R2 = 0.98-0.99). When EPL plans were recalculated with MC, the mean doses to OARs 
decreased by 12% in the lung, 4% in the ribs and 11% in the spine, oesophagus, heart and 
bronchus (fi gure 3). The maximum doses to OARs decreased by 12% in the lung, 5% in the 
ribs, 7% in the spine, 6% in the oesophagus, 8% in the heart and 9% in the bronchus. 
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Figure 3. Comparison of EPL and MC mean dose (Gy) to the OARs (lung, rib, spine, oesophagus, heart 
and bronchus).
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Correlation test and Multivariate analysis
The GTV, tumor diameter, peripheral or central tumor location, cone size and the minimal 
distance between the tumor to soft tissue (dmin) were all associated with the magnitude of 
dose reduction when EPL plans were recalculated with MC. A multivariate regression analy-
sis with GTV, peripheral or central tumor location and dmin as prognostic variables indicated 
that only dmin and GTV remained associated with the magnitude of dose reduction. As tumor 
diameter and cone size were highly correlated to the GTV, these variables were excluded 
from the multivariate analysis. 
Monte Carlo Dose Prescription 
Based on the median reduction in D95, the EPL dose to peripheral tumors (3 x 20 Gy) can 
be converted to the following MC prescription doses: 3 x 16 Gy for tumors <3 cm, 3 x 17 
Gy for tumors of 3-5 cm and 3 x 18 Gy for tumors >5 cm. In central tumors located near the 
oesophagus the EPL dose (6 x 8 Gy) can be converted to the following MC dose: 6 x 7 Gy 
for tumors of 3-5 cm and 6 x 7.3 Gy for tumors >5 cm. The EPL fraction dose to all other 
central tumors (5 x 12 Gy) can be converted to 10.4 Gy per fraction for tumors of 3-5 cm and 
11 Gy per fraction for tumors >5 cm. 
The heterogeneity index for peripheral tumors ranged from 72-90% in EPL recalculated 
plans and from 64-80% in MC recalculated plans. The HI was lower than 70% in only four 
plans (fi gure 4). The HI for central tumors ranged from 64-83% in EPL recalculated plans 
and from 61-79% in MC recalculated plans. 
For peripheral tumors, the average dose parameters (D95, D99 and mean dose) did not 
differ signifi cantly in 1) plans prescribed with MC and 2) plans prescribed with EPL and 
re-calculated with MC (table 3). 
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Figure 4. Distribution of the heterogeneity index calculated with EPL and MC for treatment plans of 
peripheral and central tumors. 
Table 3. Average difference in dose parameters for plans prescribed with MC and plans prescribed with 
EPL (3 x 20 Gy) and recalculated with MC.
Average dose difference (Gy) Range in dose difference (Gy) Paired T-test
D95
< 3 cm -0.4 -9.0 – 6.9 0.78
3-5 cm 0.1 -4.6 – 8.4 0.92
> 5 cm 0 -2.3 – 3.4 0.99
D99 
< 3 cm -0.4 -8.6 – 6.3 0.75
3-5 cm 0 -4.4 – 7.8 0.93
> 5 cm 0 -2.2 – 3.2 1.0
Mean dose
< 3 cm -0.3 -10.0 – 8.0 0.83
3-5 cm 0.2 -5.1 – 10.0 0.87
> 5 cm 0.1 -2.5 – 3.8 0.95
D95: dose to 95% of the planning target volume, D99: dose to 99% of the planning target volume
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Discussion 
The validity of this study is based on a previous in-house validation of the MC algorithm 
used by Multiplan. The MC algorithm in Multiplan includes a number of simplifi cations 
intended to improve calculation speed. These include a measurement based virtual source 
model and variance reduction techniques (16-19). Despite these simplifi cations, the MC 
algorithm predicted dose within 3% of the measured dose in an anthropomorphic chest 
phantom (15). As the MC-calculated dose closely refl ects the actual delivered dose, our 
results show that for peripheral tumors, EPL overestimates the dose delivered to 95% of the 
PTV by on average 21% in tumors <3 cm, 17% in tumors of 3-5 cm and 10% in tumors > 5 
cm. The overestimation of dose delivered to central tumors is slightly lower: 12% in tumors 
of 3-5 cm and 8% in tumors >5 cm. Our results also imply that we are currently treating 
tumors with a wide range of doses as the dose calculated with MC deviated from the EPL 
dose by 6-33% for peripheral tumors and 3-22% for central tumors. Doses to OARs were 
also overestimated by the EPL algorithm. As EPL and MC doses to OARs correlate strongly, 
a simple conversion can be done from EPL to MC. 
Other treatment planning studies also show that the EPL algorithm overestimates the dose 
delivered to pulmonary targets and that the discrepancy between planned and delivered dose 
varies widely. The EPL algorithm overestimated the mean dose to 72 pulmonary targets 
by on average 19% (range: 4-40%) compared with MC derived doses (4). A second study 
compared the dose to pulmonary targets calculated with EPL and the more accurate col-
lapsed cone algorithm (5). EPL overestimated the dose to 95% of the PTV by on average 
20% (7-43%). The dose to 95% of the PTV was overestimated most in small tumors. In a 
third study EPL overestimated the dose to 95% of the PTV by up to 40% of the prescribed 
dose compared with the more accurate anisotropic analytical algorithm (8). These studies 
all underline the inaccuracy of EPL dose calculation, but none suggest a prescription dose 
based on the more accurate algorithms. As the size of EPL dose calculation errors depend on 
multiple factors, a simply rescaling of the prescription dose is not possible. Despite this, it is 
generally agreed that dose adjustments are necessary to avoid an increase in dose levels, as 
this may increase morbidity (22, 23). 
Our aim was to adjust the MC prescription dose for peripheral tumors so that it approached 
the current EPL dose of 3 x 20 Gy. This was the aim because local tumor control was high 
(96%) and toxicity was low (10%) at this EPL dose (2). Depending on tumor size, we pro-
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pose a MC prescription dose of 16-18 Gy for peripheral tumors. For central tumors, the 
prescription dose can be converted from EPL to MC by reducing the EPL dose by 13% in 
tumors of 3-5 cm and by 9% in tumors > 5 cm. We cannot provide a MC prescription dose 
for central tumors at this point as the EPL dose recommendation for central tumors at our 
institute needs to be assessed after longer follow-up. 
A separate dose recommendation was given for tumors < 3 cm, tumors of 3-5 cm and tumors 
> 5 cm as tumor size was shown to infl uence dose calculations (5, 8). Tumors smaller than 
2.5-3 cm were more susceptible to 20% or higher differences in mean and minimum target 
dose (4). Distinguishing tumors according to tumor size also seems reasonable from a clini-
cal point of view as large tumors may require a higher dose to achieve local tumor control 
(1, 2, 24, 25). 
For peripheral tumors, we showed that the average dose parameters (D95, D99 and mean 
dose) did not differ signifi cantly in 1) plans prescribed with MC and 2) plans prescribed with 
EPL and re-calculated with MC (table 3). Monte Carlo optimization was not required in the 
majority of cases as the HI was above 70% in all but four MC recalculated plans. Therefore 
it was feasible to prescribe dose to plans re-calculated but not re-optimized with MC as long 
as a HI ≥70% is accepted. The lack of optimization was pointed out in a comment concerning 
the publication by Xiao et al. In contrast to Xiao’s study, we optimized our treatment plans 
using EPL rather than no correction at all. Optimization using MC provides the possibility to 
further improve already acceptable treatment plans. 
Although conversions of prescription dose from EPL to MC have not yet been published, 
conversions from other simple to more complex algorithms have been published for non-
CyberKnife treatments. The Dutch ROSEL study recommended 3 fractions of 20 Gy when 
calculations were based on “type a” algorithms (such as the EPL algorithm) and 3 fractions 
of 18 Gy when treatment planning was based on more accurate “type b” algorithms (22). A 
study based on the RTOG 0236 trial suggested 3 fractions of 18-19 Gy when converting from 
dose calculation based on unit density to “type b” dose calculation (23). These studies did 
not provide a recommendation based on tumor size and the recommended dose was higher 
than our recommendation. The RTOG recommendation is probably higher than our recom-
mendation because the current actual delivered dose is higher in the RTOG trial (3 x 20 Gy 
based on unit density without heterogeneity correction is a higher dose than 3 x 20 Gy based 
on EPL). Further research is recommended to defi ne a new dose-effect relationship for MC 
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prescribed plans; either in prospective clinical trials or through retrospective analysis aimed 
at determining the true tumor control probability and normal tissue complication probability 
using MC recalculated plans. 
Conclusion
The EPL algorithm overestimates the actual delivered dose and we are currently treating 
tumors with a wide range of doses. For a conversion from EPL to MC, we recommend a 
separate prescription dose according to tumor size. For peripheral tumors we recommend the 
following dose schedules: 3 x 16 Gy for tumors <3 cm, 3 x 17 Gy for tumors of 3-5 cm and 3 
x 18 Gy for tumors >5 cm. If the dose is prescribed to the D95 and a HI of 70% is accepted, 
then for most patients it is not necessary to optimize treatment plans with MC. As the dose 
to organs at risk calculated with EPL and MC correlate strongly, a simple conversion can be 
done to obtain MC dose constraints. For central tumors, a dose recommendation cannot be 
given at this moment as our EPL dose schedules for central tumors need to be assessed after 
longer follow-up.
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Discussion
The treatment of choice for patients with stage I non-small cell lung cancer is surgery. De-
spite this, many patients with operable tumors cannot tolerate surgery due to smoking-related 
comorbity. The problem of inoperability due to severe comorbidity and patient frailty is 
expected to increase as the life expectancy of the general population increases. For inoper-
able patients with stage I non-small cell lung cancer (NSCLC) the results of conventional 
3D-conformal radiotherapy have been disappointing. Long-term survival rates ranged from 
5-30% and are far inferior to surgical results of 50-70% (1-3). It is known from conventional 
radiotherapy studies that higher radiation doses improve not only local tumor control but also 
improve the overall survival of NSCLC patients (3, 4). Dose escalation is however limited by 
the typically large radiation fi elds that are required to account for geometrical uncertainties 
related to patient set-up and tumor motion. The introduction of stereotactic radiotherapy has 
enabled dose escalation without increasing toxicity, as the radiation dose is precisely targeted 
and delivered to the tumor, while respiratory tumor motion is accounted for. Although there 
are several stereotactic radiotherapy systems, characteristic to all stereotactic radiotherapy 
(SRT) treatments is the precise delivery of large fraction sizes in a short overall treatment 
time.
At the Erasmus MC Daniel den Hoed Oncology Center, stage I NSCLC patients are treated 
with the CyberKnife stereotactic radiotherapy system using real-time respiratory tumor 
tracking. Real-time tumor tracking corrects for tumor motion during respiration by reposi-
tioning the radiation beam to the position of the moving tumor. As the tumor is not directly 
visible during treatment, this technique requires the insertion of radio-opaque markers in or 
near the tumor. In order to accurately target the tumor, it is essential that the position of the 
markers remain stable relative to the position of the tumor. The stability of these surrogate 
markers has been reported in chapter 2. The markers were placed via the percutaneous intra-
pulmonary approach. Similar to other studies (5, 6), our results show that markers placed via 
the percutaneous intrapulmonary approach are generally stable, with a median displacement 
of 1.3 mm. However, large displacements in marker position may occur; 12% of markers 
were displaced by more than 5 mm and 5% of the markers were displaced by more than 
10 mm. As marker displacements may be large, we recommend the placement of multiple 
markers. Multiple markers enable a reliable check for marker displacement as changes in 
the marker confi guration are easily detected. This is not possible if a single marker is used. 
Displacement of a single marker may therefore remain undetected and cause systematic, 
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potentially dangerous localization errors. An argument against the use of multiple markers 
is the higher risk of a pneumothorax when multiple markers are implanted. This risk has 
however been reduced by the development of transbronchial, trans-oesophageal and vascular 
marker placement techniques (7-9). 
Stereotactic radiotherapy has emerged as an important treatment modality for inoperable 
patients with stage I NSCLC. In chapter 3 the results of stereotactic radiotherapy using 
real-time tumor tracking are reported for 70 patients with stage I NSCLC. The local tumor 
control rate and treatment-related toxicity after real-time tumor tracking are comparable 
to the outcomes reported after treatment using other stereotactic radiotherapy approaches. 
Although not statistically signifi cant, the actuarial local tumor control rate was higher in 
patients treated with a higher radiation dose (96% using 60 Gy versus 78% using 45 Gy) and 
for patients with smaller tumors (100% for T1 tumors versus 89% for T2 tumors). As merely 
four local recurrences were observed in our study, it is not possible to make conclusions 
about the infl uence of radiation dose and tumor size on local tumor control. Nevertheless it 
is interesting to note that other studies have also observed lower tumor control rates for lower 
radiation doses and larger tumors (10). The two-year overall survival rate in our study was 
62% compared with 64-83% reported in the literature (11, 12). Presumably patient selection 
plays a role in the variation of overall survival. A drawback of our study is the absence of 
pathologic confi rmation of malignancy in 49% of patients. In these patients, the risk of ob-
taining pathology via trans-thoracic biopsies was too high due to poor pulmonary function. 
This is a common problem in radiotherapy studies. Nevertheless, the risk of malignancy is 
very high in older patients with a growing lesion on the CT-scan, a corresponding avid lesion 
on the PET-scan, and a history of smoking (13). Taking this into account, the local tumor 
control rates achieved after stereotactic radiotherapy are high and stereotactic radiotherapy 
should be considered as a good alternative for inoperable patients with stage I NSCLC. 
As the incidence of octogenarians with stage I NSCLC increases, and only selected patients 
are surgical candidates, it is important to investigate the role of stereotactic radiotherapy in 
this particular patient population. Chapter 4 reports the outcome of stereotactic radiotherapy 
in 38 octogenarians with stage I NSCLC. In this population the rate of comorbidity was high 
(Charlson comorbidity score >5 in 16% of patients). Despite this, the local tumor control 
rate was excellent while toxicity related to marker placement and treatment was low. Five 
percent of patients had toxicity related to marker placement, 5% of patients had acute grade 
3 toxicity and 16% of patients had late grade 3 toxicity after treatment. The overall survival 
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in octogenarians treated in our study is however low compared with surgical series (44% 
versus 34-79% at two years) (14-16). This difference in overall survival is not surprising as 
surgical series carefully select physically fi t octogenarians. Despite careful patient selection, 
the current rates of mortality still vary enormously after surgery in octogenarians (0-15%) 
(14, 16-19). Favorable outcomes are reported after limited resections performed in high 
volume hospitals. Although not all octogenarians will be suitable candidates for surgery, best 
supportive care cannot always be justifi ed. The two-year overall survival of untreated stage I 
NSCLC was merely 8% (20). The treatment of octogenarians with stage I NSCLC remains a 
challenge due to patient frailty and comorbidity. Unfortunately randomized trials are lacking 
and cannot guide treatment decisions. Despite the size of our study, our results show that 
stereotactic radiotherapy should be considered in octogenarians in whom the surgical risk is 
high, even when they have severe comorbidity. 
Although improvement of local tumor control and overall survival are the main goal of any 
cancer treatment, an equally important aim is to maintain or improve the patients’ quality 
of life (QoL). The impact of treatment on the QoL is especially relevant in patients with 
NSCLC, given the limited overall survival and the high level of comorbidity in the majority 
of these patients. Chapter 5 reports the impact of stereotactic radiotherapy on the quality 
of life of 39 patients with inoperable, pathology-proven, stage I NSCLC. The European 
Organization for Research and Treatment of Cancer Quality of Life Questionnaire (EORTC 
QLQ-C30) and the lung cancer-specifi c questionnaire (EORTC QLQ-LC13) were used to 
investigate changes in quality of life. Assessments were done before treatment and at regular 
intervals after treatment. Global health status and respiratory symptoms did not deteriorate 
after stereotactic radiotherapy. The only signifi cant change observed for QoL scores at every 
time interval was an improved emotional functioning score. Despite the limited size of our 
study, the lack of large changes in the QoL scores shows that patients with stage I NSCLC 
can be treated with stereotactic radiotherapy without causing signifi cant deterioration in the 
patients’ quality of life.
Despite the promising treatment outcomes after stereotactic radiotherapy, large deviations in 
planned and delivered dose are found when treatment planning is based on dose calculation 
using simple heterogeneity correction algorithms (21-24). In chapter 6 fi fty-three treatment 
plans calculated with the equivalent path-length algorithm (EPL) were compared to the same 
treatment plans recalculated with the more accurate Monte Carlo algorithm (MC). Our results 
showed that the EPL algorithm overestimated the delivered dose by 6-33%. This implies that 
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we are currently treating tumors with a wide range of doses. An aim of our study was to 
propose a Monte Carlo prescription dose that approached the EPL prescription dose (3 x 20 
Gy). As the EPL dose is overestimated most in small tumors, we recommend a different MC 
prescription dose according to tumor size. Based on the reduction in dose to 95% of the plan-
ning target volume, the EPL dose to peripheral tumors can be converted to a MC prescription 
dose of 3 x 16-18 Gy depending on the tumor size. Distinguishing tumors according to tumor 
size also seems reasonable from a clinical point of view as large tumors may require a higher 
dose to achieve local tumor control (10, 11, 25, 26). The dose constraints to organs at risk can 
be easily converted due to the high EPL-MC correlation. Other treatment planning studies 
also underline the inaccuracy of the EPL dose calculation algorithm. A study based on the 
RTOG 0236 trial suggested 3 fractions of 18-19 Gy when converting to a more accurate dose 
calculation algorithm (27). This recommendation is higher than ours, but the initial delivered 
dose was also higher (as 3 x 20 Gy unit density without heterogeneity correction is a higher 
dose than 3 x 20 Gy based on EPL). 
Future Directions
The use of more accurate dose calculation algorithms will give more insight into the actual 
dose-effect relationship and will also facilitate the comparison of treatment outcomes in 
clinical trials. The Monte Carlo calculation algorithm is the most accurate dose calcula-
tion algorithm currently available. It can now be used in clinical practice as the calculation 
times have been drastically reduced by high performance computers and variance reduction 
techniques. In chapter 6 we provided a recommendation for MC dose prescription. Further 
research is recommended to verify these prescription doses and to defi ne a new dose-effect 
relationship for MC prescribed plans. This can be done either in prospective clinical trials or 
through retrospective analysis aimed at determining the true tumor control probability and 
normal tissue complication probability using MC re-calculated plans.
The majority of patients treated with stereotactic radiotherapy are inoperable patients and 
have peripherally located tumors. The experience with stereotactic radiotherapy in centrally 
located tumors is still limited. Risk-adaptive treatment schedules are currently used, as se-
vere toxicity was reported after treatment with 60-66 Gy in three fractions (28). To determine 
the role of stereotactic radiotherapy in centrally located tumors, more research is needed 
to assess the long-term outcome after using the risk-adaptive treatment schedule. It is also 
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of great interest to examine the role of stereotactic radiotherapy in operable patients with 
stage I NSCLC. Although surgery is the treatment of choice for operable patients with stage 
I NSCLC, stereotactic radiotherapy may be a less-invasive and good alternative. A multi-
institutional Japanese study reported promising outcome in a subgroup of operable patients 
treated with stereotactic radiotherapy. The local tumor control rate was >90% when operable 
patients were treated with a biological effective dose ≥100 Gy (11). These outcomes are 
comparable to those reported after surgery. Results from prospective randomized trials com-
paring surgery to stereotactic radiotherapy are on their way. One of these trials is the STARS 
trial, an international randomized study to compare CyberKnife stereotactic radiotherapy 
with surgical resection in stage I NSCLC. The other is the Dutch ROSEL trial.
In addition to the treatment of non-small cell lung cancer, the experience with stereotactic ra-
diotherapy has been carefully extended to patients with oligometastases to the lung. Okunieff 
reported an excellent local tumor control rate of 91% at three years with the delivery of 50-55 
Gy in 5 fractions (29). At our institute we are currently enrolling patients with a maximum of 
5 oligometastases to the LUMERAS study. The aim of this single arm non-randomized trial 
is to determine whether stereotactic radiotherapy can achieve local tumor control rates of at 
least 90% in patients with lung metastases, an outcome considered comparable to surgery.
Conclusions
• Markers placed via the percutaneous intrapulmonary approach are generally stable but 
large displacements may occur.
• The placement of multiple markers is recommended for real-time tumor tracking as this 
allows marker displacements to be easily detected by changes in the marker confi guration.
• The results after stereotactic radiotherapy using real-time tumor tracking are excellent 
and similar to those achieved using other stereotactic radiotherapy systems (two year 
local tumor control rate of 96% when treated with 60 Gy).
• Stereotactic radiotherapy should be considered in elderly patients even in the presence of 
multiple comorbidities.
• Patients with stage I NSCLC can be treated with stereotactic radiotherapy without causing 
signifi cant deterioration in the quality of life.
• Emotional functioning improves in patients with stage I NSCLC after treatment with 
stereotactic radiotherapy using the CyberKnife.
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• Simple dose calculation algorithms such as the Equivalent path-length algorithm over-
estimate the dose delivered to the planning target volume.
• For the conversion from equivalent pathlength (EPL) dose calculation to Monte Carlo 
(MC) dose calculation we recommend a different prescription dose according to tumor 
size (3 x 16 Gy for tumors <3 cm, 3 x 17 Gy for tumors of 3-5 cm, and 3 x 18 Gy for 
tumors >5 cm).
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Samenvatting
Chirurgie is de eerste keuze bij de behandeling van patiënten met een stadium I niet-klein-
cellig longcarcinoom (NKCLC). Veel van deze patiënten zijn echter inoperabel vanwege 
comorbiditeit. Inoperabiliteit op basis van comorbiditeit zal naar verwachting toenemen om-
dat de levensverwachting van de algemene bevolking stijgt. Voor inoperabele patiënten met 
een stadium I NKCLC zijn de resultaten van conventionele 3D-conformatie radiotherapie 
teleurstellend. Het overlevingspercentage is inferieur aan die van chirurgie (5-30% versus 
50-70%) (1-3). Uit studies blijkt dat een hogere bestralingsdosis niet alleen de lokale tumor-
controle verbetert van patiënten met een NKCLC, maar ook de overlevingkans (3, 4). Een 
verhoging van de dosis wordt echter beperkt door de grote bestralingsvelden die doorgaans 
nodig zijn om te compenseren voor tumorbeweging en de onzekerheid in de exacte ligging 
van de patiënt. Met de introductie van stereotactische radiotherapie kan de bestralingsbundel 
nauwkeuriger op de tumor worden gericht. Hierdoor kan de grootte van de bestralingsvelden 
worden beperkt en de dosis worden verhoogd zonder dat de bijwerkingen van de behande-
ling toenemen. Er bestaan verschillende systemen waarmee stereotactische radiotherapie kan 
worden uitgevoerd, maar karakteristiek voor alle stereotactische radiotherapie behandelingen 
is dat in een kort tijdsbestek een hoge dosis word toegediend. 
In het Erasmus MC Daniel den Hoed Oncologisch Centrum worden patiënten met een sta-
dium I NKSLC behandeld met het CyberKnife stereotactisch radiotherapie systeem, dat is 
uitgevoerd met “real-time respiratory tumor tracking”. “Real-time tumor tracking” corrigeert 
voor tumorbeweging als gevolg van de ademhaling door de bestralingsbundel de bewegende 
tumor te laten volgen. Omdat de tumor niet direct zichtbaar is tijdens de behandeling worden 
er radiopake markers geplaatst in of nabij de tumor. Om de bestralingsbundel nauwkeurig op 
de tumor te kunnen richten, is het essentieel dat de markers ten opzichte van de tumor niet 
verplaatsen (hoofdstuk 2). De markers worden via de percutane intrapulmonale techniek 
geplaatst. Onze resultaten tonen dat de markers zich over het algemeen niet verplaatsen ten 
opzichte van de tumor (mediane verplaatsing van 1.3 mm). Dit komt overeen met de resul-
taten van andere studies (5, 6). Grote verplaatsingen kunnen echter voorkomen; 12% van 
de markers waren meer dan 5 mm verplaatst en 5% van de markers waren meer dan 10 mm 
verplaatst. Omdat de verplaatsing van een marker groot kan zijn, raden wij aan om meer dan 
één marker te plaatsen. Het plaatsen van meer dan één marker maakt het mogelijk om marker 
verplaatsingen op eenvoudige wijze op te sporen door de onderlinge afstand van de markers 
te controleren. Dit is niet mogelijk als een enkele marker wordt geplaatst. De verplaatsing 
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van een enkele marker kan onopgemerkt blijven en leiden tot een grote systematische fout 
in het richten van de bestralingsbundel op de tumor. Een argument tegen het plaatsen van 
meer dan één marker is het grotere risico op een klaplong. Dit risico is echter gereduceerd 
door de ontwikkeling van alternatieve markerplaatsingstechnieken zoals transbronchiale, 
transoesofageale en vasculaire technieken (7-9). 
Stereotactische radiotherapie is een belangrijke behandelmodaliteit voor patiënten met 
een stadium I NKCLC. In hoofdstuk 3 rapporteren wij de resultaten van stereotactische 
radiotherapie met behulp van “real-time tumor tracking” in 70 patiënten met een stadium I 
NKCLC. De lokale tumorcontrole en de toxiciteit na “real-time tumor tracking” zijn verge-
lijkbaar met de resultaten na stereotactische radiotherapie met andere systemen. De lokale 
tumorcontrole was 96% na behandeling met 60 Gy en 78% na behandeling met 45 Gy. De 
lokale tumorcontrole was 100% voor T1 tumoren en 89% voor T2-tumoren. Het is op basis 
van onze studie niet mogelijk om conclusies te trekken over de invloed van bestralingsdosis 
en tumorgrootte op de lokale tumorcontrole aangezien er maar vier lokale tumorrecidieven 
waren. Desondanks is het opvallend dat ook andere studies een lagere lokale tumorcontrole 
hebben geobserveerd bij een lagere bestralingsdosis en bij grotere tumoren (10). De twee-
jaars-overleving was 62% in onze studie, vergeleken met 64-83% in andere studies (11, 12). 
Waarschijnlijk speelt patiëntenselectie een belangrijke rol in de variatie van de overleving. 
Een nadeel van onze studie is dat er geen pathologische bevestiging van maligniteit was 
in 49% van de patiënten. In deze patiënten was de longfunctie vaak te slecht, en het risico 
van een klaplong te groot, zodat een transthoracale bioptie niet werd verricht. Dit is een 
veelvoorkomend probleem in radiotherapie studies, aangezien patiënten met een acceptabele 
longfunctie meestal geopereerd worden. Desondanks is het risico op maligniteit groot bij 
patienten in deze oudere rokende bevolkingsgroep die een groeiende lesie hebben op de 
CT-scan, en een corresponderende aankleurende afwijking op de PET-scan (13). Hiervan 
uitgaande, is de lokale tumorcontrole na stereotactische radiotherapie hoog. Stereotactische 
radiotherapie kan als een goed alternatief voor chirurgie worden beschouwd in inoperabele 
patiënten met een stadium I NKCLC. 
Het is van belang om de rol van stereotactische radiotherapie bij ouderen te onderzoeken 
aangezien het aantal ouderen met een stadium I NKCLC toeneemt en veel van deze patiënten 
geen geschikte kandidaten zijn voor een chirurgische behandeling. Hoofdstuk 4 beschrijft 
de resultaten van stereotactische radiotherapie in 38 patiënten van 80 jaar en ouder met een 
stadium I NKCLC en met veel comorbiditeit (Charlson comorbiditeit score >5 in 16% van de 
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patiënten). Desondanks is de lokale tumorcontrole uitstekend en zijn er weinig bijwerkingen 
van de markerplaatsing en de bestraling. Vijf procent van de patiënten had bijwerkingen na 
markerplaatsing. Na de bestraling had 5% van de patiënten acute graad 3 bijwerkingen en 
16% van de patiënten had late graad 3 bijwerkingen. De overleving van tachtigjarigen na 
stereotactische radiotherapie is echter kort vergeleken met chirurgische studies (44% versus 
34-79% na 2 jaar) (14-16). Het verschil in overleving is echter niet verassend aangezien 
chirurgische studies zeer zorgvuldig patiënten selecteren met een goede conditie. Ondanks 
de zorgvuldige patiëntenselectie, varieert de mortaliteit aanzienlijk na een chirurgische 
behandeling van tachtigjarigen (0-15%) (14, 16-19). Er worden betere uitkomsten gerap-
porteerd na beperkte resecties in gespecialiseerde centra. Helaas komen lang niet alle tach-
tigjarigen in aanmerking voor een chirurgische behandeling. “Best supportive care” in deze 
patiënten is echter niet altijd gerechtvaardigd. De twee-jaars-overleving van patienten met 
een onbehandeld stadium I NKCLC was slechts 8% (20). De behandeling van tachtigjarigen 
met een stadium I NKCLC blijft uitdagend door de kwetsbaarheid van deze patiënten, en de 
hoge incidentie van comorbiditeit. Helaas ontbreken gerandomiseerde studies om keuzes 
in de behandeling te vergemakkelijken. De grootte van onze studie is beperkt. Desondanks 
toont onze studie aan dat stereotactische radiotherapie een goede behandeloptie is bij tach-
tigjarigen die niet in aanmerking komen voor een chirurgische behandeling, zelfs wanneer er 
sprake is van veel comorbiditeit. 
De verbetering van overleving en lokale tumorcontrole zijn de primaire doelen van elke 
kankerbehandeling. Even belangrijk is het behouden of verbeteren van de kwaliteit van leven 
(QoL) van de patiënt. De invloed van een behandeling op de QoL is vooral van belang bij pa-
tiënten met een NKCLC omdat de overlevingsduur beperkt is en de incidentie van comorbi-
diteit in deze patiëntengroep hoog is. Hoofdstuk 5 rapporteert de invloed van stereotactische 
radiotherapie op de kwaliteit van leven bij 39 patiënten met een niet operabel, pathologisch 
bewezen stadium I NKCLC. De “European Organization for Research and Treatment of 
Cancer Quality of Life Questionnaire” (EORTC QLQ-C30) en de longkanker specifi eke 
vragenlijst (EORTC QLQ-LC13) werden gebruikt om veranderingen in de kwaliteit van 
leven op te sporen. De vragenlijsten werden voor de behandeling ingevuld en op regelmatige 
intervallen na de behandeling. De globale gezondheid en respiratoire symptomen bleven 
onveranderd na stereotactische radiotherapie. De enige signifi cante verandering in QoL 
scores was een verbetering in het emotioneel functioneren. Ondanks de beperkte grootte van 
onze studie laat de afwezigheid van grote veranderingen in QoL zien dat patiënten met een 
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stadium I NKCLC behandeld kunnen worden met stereotactische radiotherapie zonder dat 
dit een signifi cante verslechtering van de kwaliteit van leven geeft. 
De uitkomsten van stereotactische radiotherapie zijn veel belovend. Desondanks worden er 
grote verschillen gezien in de bestralingsdosis als deze wordt berekend met een eenvoudig 
of een geavanceerd algoritme (21-24). Hoofdstuk 6 vergelijkt de dosis van 53 bestralings-
plannen berekend met het “equivalent path-length algoritme” (EPL), en daarna herberekend 
met het nauwkeurigere “Monte Carlo algoritme” (MC). Onze resultaten laten zien dat de 
dosisberekening met het EPL algoritme de gegeven bestralingsdosis overschat met 6-33%. 
Dit impliceert dat tumoren op dit moment worden behandeld met een zeer uiteenlopende 
dosis. Een van de doelen van onze studie was om een aanbeveling te maken voor een MC 
dosisvoorschrift welke het huidige EPL dosis voorschrift benadert (3 x 20 Gy). Aangezien 
de EPL dosis het meest wordt overschat in kleine tumoren, raden wij aan om de MC dosis 
te laten afhangen van de grootte van de tumor. Op basis van de afname in D95 (dosis in 
95% van het PTV), stellen wij voor om de EPL dosis om te zetten naar een MC voorschrift 
van 3 x 16 Gy, 3 x 17 Gy, of 3 x 18 Gy afhankelijk van de tumorgrootte. Het onderscheid in 
tumorgrootte lijkt ook klinisch relevant omdat grotere tumoren mogelijk een hogere dosis 
nodig hebben om lokale tumorcontrole te bereiken (10, 11, 25, 26). De dosis “constraints” 
voor gezonde weefsels kunnen gemakkelijk worden omgerekend doordat de EPL en MC 
dosis voor de gezonde weefsels sterk aan elkaar gecorreleerd zijn. Andere treatment planning 
studies benadrukken ook de onnauwkeurigheid van het EPL dosisberekeningsalgoritme. 
Een studie gebaseerd op de RTOG 0236 trial suggereert 3 fracties van 18-19 Gy indien 
nauwkeurigere algoritmes worden gebruikt (27). Deze aanbeveling is hoger dan die van ons 
(3 x 16-18 Gy) omdat het oorspronkelijke dosisvoorschrift in die studie was gebaseerd op 3 
x 20 Gy “ unit density” zonder heterogeniteitscorretie (hetgeen een hogere dosis is dan 3 x 
20 Gy EPL).
Toekomst Perspectieven
Het gebruik van een nauwkeuriger algoritme voor dosisberekening zal niet alleen een beter 
inzicht geven in de werkelijke dose-effect relatie, maar het zal ook de vergelijking van behan-
deluitkomsten vergemakkelijken. Het Monte Carlo algoritme is nu het meest nauwkeurige 
dosisberekeningsalgoritme. Het kan tegenwoordig in de praktijk worden toegepast omdat 
de berekentijden drastisch zijn verlaagd door “high performance” computers en “variance 
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reduction” technieken. In hoofdstuk 6 geven wij een aanbeveling voor MC gebaseerde 
dosisvoorschriften. Aanvullend onderzoek is nodig om de nieuwe MC dosisvoorschiften te 
verifi ëren en een nieuwe dosis-effect relatie te defi niëren voor dosisverdelingen berekend 
met MC. Dit kan via prospectieve klinische studies worden onderzocht of via retrospectieve 
analyse, waarij bestaande bestralingsplannen worden herberekend met MC en de MC dosis 
wordt gerelateerd aan 1) de lokale tumorcontrole en 2) de incidentie van complicaties. 
Het merendeel van de patiënten die met stereotactische radiotherapie worden behandeld 
zijn inoperabel en hebben perifeer gelegen tumoren. De ervaring met stereotactische ra-
diotherapie bij patiënten met een centraal gelegen tumor is nog beperkt. Risicoaangepaste 
behandelschema’s worden op dit moment gebruikt aangezien ernstige toxiciteit is gemeld bij 
een dosis van 60-66 Gy in drie fracties (28). Om de rol van stereotactische radiotherapie bij 
patiënten met een centraal gelegen tumor te bepalen is aanvullend onderzoek nodig om de 
uitkomst na langere termijn van aangepaste schema’s te bepalen. De rol van stereotactische 
radiotherapie bij operabele patiënten met een stadium I NKCLC staat in de belangstelling. 
Voor operabele patiënten met een stadium I NKCLC heeft chirurgische behandeling de voor-
keur. Desondanks kan stereotactische radiotherapie een minder invasief en goed alternatief 
zijn. Een multi-institutionele Japanse studie rapporteerde een veel belovend resultaat na ste-
reotactische radiotherapie in een subgroep van operabele patiënten. Bij operabele patiënten 
behandeld met een biologische effectieve dosis ≥100 Gy was de lokaal tumorcontrole >90% 
(11). Deze uitkomsten zijn vergelijkbaar met die na chirurgie. Prospectief gerandomiseerde 
studies die chirurgie vergelijken met stereotactische radiotherapie zijn gestart. Een hiervan 
is de STARS trial, een internationale studie die CyberKnife stereotactische radiotherapie 
vergelijkt met chirurgische resectie van een stadium I NKCLC. Een andere studie is de 
Nederlandse ROSEL trial. 
Naast de behandeling van patiënten met een niet-kleincellig longcarcinoom, wordt de erva-
ring met stereotactische radiotherapie nu voorzichtig uitgebreid naar patiënten met oligome-
tastasen in de long. Okunieff rapporteerde een uitstekend lokale tumorcontrole van 91% na 
drie jaar met 50-55 Gy in 5 fracties (29). In het Erasmus MC Daniel den Hoed Oncologisch 
Centrum worden op dit moment patiënten met maximaal 5 oligometastasen geïncludeerd in 
de LUMERAS studie. Het doel van deze “single-arm”, niet gerandomiseerde studie is om 
te bepalen of stereotactische radiotherapie een lokale tumorcontrole van tenminste 90% kan 
bereiken in patiënten met long metastasen; een uitkomst die vergelijkbaar wordt geacht aan 
chirurgische behandeling.
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Conclusies
• Markers die geplaatst worden via de percutane intrapulmonale techniek zijn over het 
algemeen stabiel; er kunnen echter grote verschuivingen optreden.
• Het is raadzaam om meer dan één marker te plaatsen voor “real-time tumor tracking” aan-
gezien multipele markers het mogelijk maken om marker verplaatsingen op eenvoudige 
wijze op te sporen door de onderlinge afstand van de markers te controleren.
• De resultaten van stereotactische radiotherapie met “real-time tumor tracking” zijn 
uitstekend en vergelijkbaar met de resultaten na behandeling met andere stereotactische 
systemen (lokale tumorcontrole na twee jaar van 96% na behandeling met 60 Gy).
• Stereotactische radiotherapie moet overwogen worden bij de behandeling van ouderen, 
ook bij de aanwezigheid van comorbiditeit.
• Patiënten met een stadium I NKCLC kunnen behandeld worden met stereotactische 
radiotherapie zonder dat hun kwaliteit van leven signifi cant afneemt.
• Het emotioneel functioneren verbetert signifi cant in patiënten met een stadium I NKCLC 
die behandeld zijn met stereotactische radiotherapie door middel van het CyberKnife.
• Simpele dosis berekeningsalgoritmes zoals het “equivalent pathlength” algoritme over-
schatten de dosis in het “planning target volume”.
• Voor het omrekenen van de dosis met “equivalent pathlength” naar Monte Carlo (MC) 
raden wij aan om de MC dosis voor te schrijven op basis van tumor-grootte (3 x 16 Gy 
voor tumoren <3 cm, 3 x 17 Gy voor tumoren van 3-5 cm, en 3 x 18 Gy voor tumoren >5 
cm).
Noelle bw.indd   122 29-03-11   17:05
 Chapter 8 ■ 123
Referenties
 1. Sibley GS, Jamieson TA, Marks LB, et al. Radiotherapy alone for medically inoperable stage I non-
small-cell lung cancer: the Duke experience. Int J Radiat Oncol Biol Phys 1998;40:149-154.
 2. Dosoretz DE, Katin MJ, Blitzer PH, et al. Medically Inoperable Lung Carcinoma: The Role of Radiation 
Therapy. Semin Radiat Oncol 1996;6:98-104.
 3. Kong FM, Ten Haken RK, Schipper MJ, et al. High-dose radiation improved local tumor control and 
overall survival in patients with inoperable/unresectable non-small-cell lung cancer: long-term results 
of a radiation dose escalation study. Int J Radiat Oncol Biol Phys 2005;63:324-333.
 4. Belderbos JS, Heemsbergen WD, De Jaeger K, et al. Final results of a Phase I/II dose escalation trial 
in non-small-cell lung cancer using three-dimensional conformal radiotherapy. Int J Radiat Oncol Biol 
Phys 2006;66:126-134.
 5. Imura M, Yamazaki K, Shirato H, et al. Insertion and fi xation of fi ducial markers for setup and tracking 
of lung tumors in radiotherapy. Int J Radiat Oncol Biol Phys 2005;63:1442-1447.
 6. Kupelian PA, Forbes A, Willoughby TR, et al. Implantation and stability of metallic fi ducials within 
pulmonary lesions. Int J Radiat Oncol Biol Phys 2007;69:777-785.
 7. Anantham D, Feller-Kopman D, Shanmugham LN, et al. Electromagnetic navigation bronchoscopy-
guided fi ducial placement for robotic stereotactic radiosurgery of lung tumors: a feasibility study. Chest 
2007;132:930-935.
 8. Prevost JB, Nuyttens JJ, Hoogeman MS, et al. Endovascular coils as lung tumour markers in real-time 
tumour tracking stereotactic radiotherapy: preliminary results. Eur Radiol 2008;18:1569-1576.
 9. Pishvaian AC, Collins B, Gagnon G, et al. EUS-guided fi ducial placement for CyberKnife radiotherapy 
of mediastinal and abdominal malignancies. Gastrointest Endosc 2006;64:412-417.
 10. Chi A, Liao Z, Nguyen NP, et al. Systemic review of the patterns of failure following stereotactic 
body radiation therapy in early-stage non-small-cell lung cancer: clinical implications. Radiother 
Oncol;94:1-11.
 11. Onishi H, Kuriyama K, Komiyama T, et al. Clinical outcomes of stereotactic radiotherapy for stage I 
non-small cell lung cancer using a novel irradiation technique: patient self-controlled breath-hold and 
beam switching using a combination of linear accelerator and CT scanner. Lung Cancer 2004;45:45-55.
 12. Lagerwaard FJ, Haasbeek CJ, Smit EF, et al. Outcomes of risk-adapted fractionated stereotactic radio-
therapy for stage I non-small-cell lung cancer. Int J Radiat Oncol Biol Phys 2008;70:685-692.
 13. Swensen SJ, Silverstein MD, Ilstrup DM, et al. The probability of malignancy in solitary pulmonary 
nodules. Application to small radiologically indeterminate nodules. Arch Intern Med 1997;157:849-
855.
 14. Pagni S, Federico JA, Ponn RB. Pulmonary resection for lung cancer in octogenarians. Ann Thorac Surg 
1997;63:785-789.
 15. Dominguez-Ventura A, Cassivi SD, Allen MS, et al. Lung cancer in octogenarians: factors affecting 
long-term survival following resection. Eur J Cardiothorac Surg 2007;32:370-374.
Noelle bw.indd   123 29-03-11   17:05
124 ■ Chapter 8
 16. Hanagiri T, Muranaka H, Hashimoto M, et al. Results of surgical treatment of lung cancer in octogenar-
ians. Lung Cancer 1999;23:129-133.
 17. Dominguez-Ventura A, Allen MS, Cassivi SD, et al. Lung cancer in octogenarians: factors affecting 
morbidity and mortality after pulmonary resection. Ann Thorac Surg 2006;82:1175-1179.
 18. Naunheim KS, Kesler KA, D’Orazio SA, et al. Lung cancer surgery in the octogenarian. Eur J Cardio-
thorac Surg 1994;8:453-456.
 19. Ginsberg RJ, Hill LD, Eagan RT, et al. Modern thirty-day operative mortality for surgical resections in 
lung cancer. J Thorac Cardiovasc Surg 1983;86:654-658.
 20. Hillen H. Kanker bij ouderen. 2004:21,133.
 21. Lax I, Panettieri V, Wennberg B, et al. Dose distributions in SBRT of lung tumors: Comparison between 
two different treatment planning algorithms and Monte-Carlo simulation including breathing motions. 
Acta Oncol 2006;45:978-988.
 22. Rassiah-Szegedi P, Salter BJ, Fuller CD, et al. Monte Carlo characterization of target doses in stereotac-
tic body radiation therapy (SBRT). Acta Oncol 2006;45:989-994.
 23. Schuring D, Hurkmans CW. Developing and evaluating stereotactic lung RT trials: what we should 
know about the infl uence of inhomogeneity corrections on dose. Radiat Oncol 2008;3:21.
 24. Aarup LR, Nahum AE, Zacharatou C, et al. The effect of different lung densities on the accuracy of 
various radiotherapy dose calculation methods: implications for tumour coverage. Radiother Oncol 
2009;91:405-414.
 25. Baumann P, Nyman J, Lax I, et al. Factors important for effi cacy of stereotactic body radiotherapy 
of medically inoperable stage I lung cancer. A retrospective analysis of patients treated in the Nordic 
countries. Acta Oncol 2006;45:787-795.
 26. Koto M, Takai Y, Ogawa Y, et al. A phase II study on stereotactic body radiotherapy for stage I non-
small cell lung cancer. Radiother Oncol 2007;85:429-434.
 27. Xiao Y, Papiez L, Paulus R, et al. Dosimetric evaluation of heterogeneity corrections for RTOG 0236: 
stereotactic body radiotherapy of inoperable stage I-II non-small-cell lung cancer. Int J Radiat Oncol 
Biol Phys 2009;73:1235-1242.
 28. Timmerman R, McGarry R, Yiannoutsos C, et al. Excessive toxicity when treating central tumors in a 
phase II study of stereotactic body radiation therapy for medically inoperable early-stage lung cancer. J 
Clin Oncol 2006;24:4833-4839.
 29. Okunieff P, Petersen AL, Philip A, et al. Stereotactic Body Radiation Therapy (SBRT) for lung metasta-
ses. Acta Oncol 2006;45:808-817.
Noelle bw.indd   124 29-03-11   17:05
Noelle bw.indd   125 29-03-11   17:05
Noelle bw.indd   126 29-03-11   17:05
DANKWO ORD
Noelle bw.indd   127 29-03-11   17:05
Noelle bw.indd   128 29-03-11   17:05
Dankwoord ■ 129
Na een paar jaar hard werken is het nu zover….het proefschrift is geschreven en de tijd is 
aangebroken om iedereen te bedanken die mij heeft geholpen en gesteund.
Professor P.C. Levendag, u hebt mij de mogelijkheid gegeven om gedurende twee jaar mijn 
opleiding te onderbreken om onderzoek te doen. Dankzij u heb ik mij kunnen ontwikkelen 
op research gebied. Dank u wel voor alle kansen die u mij hebt gegeven en uw steun en 
vertrouwen!
Professor B.J.M. Heijmen, secretaris van de promotiecommissie, hartelijk dank voor de 
betrokkenheid bij mijn promotietraject. De twee jaar die ik heb doorgebracht op de afdeling 
fysica zijn zeer leerzaam geweest!
Overige leden van de kleine commissie: Prof. Dr. J.P. van Meerbeeck, en Prof. Dr. E.M. 
Noordijk, graag wil ik u hartelijk bedanken voor u deelname in de kleine commissie en voor 
het beoordelen van mijn proefsch rift.
Leden van de grote commissie: Prof. Dr. C.C.E. Koning en Prof. Dr. P.P Pattynama, harte-
lijke dank voor het plaatsnemen in de grote commissie en voor de tijd die u hebt besteed aan 
mijn proefschrift.
Joost Nuyttens, mijn copromotor: Beste Joost, jouw reactiesnelheid verbaasde mij keer op 
keer! De toewijding die jij hebt voor research werkt aanstekelijk. Graag wil ik jou bedanken 
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betrokkenheid!
Ronnie van der Holt: Beste Ronnie, jij hebt me veel geleerd over de statistiek. Hartelijk dank 
voor de prettige samenwerking!
Cora Braat: Heel veel dank voor al jouw inzet en ondersteuning. Zonder jou zouden de 
vragenlijsten niet zo netjes worden verstuurd/verzameld. 
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Medeauthors: Graag wil ik jullie allen bedanken voor jullie bijdrage aan de artikelen in dit 
proefschrift! Zonder jullie was het nooit zo ver gekomen.
Afdeling fysica: Lieve collega’s, ik had nooit gedacht dat ik met zoveel plezier zou terug 
kijken op de twee jaar die ik bij jullie heb mogen doorbrengen. In het begin voelde ik me een 
“verdwaalde” medicus, maar dankzij jullie is dat gauw veranderd. Dank voor alle ondersteu-
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erg gezellig….SOEP(P) comité 2009, de ESTRO in Maastricht, afspraken in Stobbe om te 
brainstormen/vieren! 
Martine Franckena: Lieve Martine, als ervaringsdeskundige heb je mij veel “promoveer” 
tips kunnen geven. Dit heeft het leven een stuk makkelijker gemaakt! Dank voor jouw goede 
voorbeeld en vriendschap! 
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Hans Knevel en Hans Vuik: heel veel dank voor de ondersteuning op audiovisueel gebied! 
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Jeanette de Vreugd: Lieve Jeanette, wat is het fi jn om ondersteund te worden door een secre-
taresse als jij! Ik hoop nog lang met jou samen te werken! 
Heel veel dank aan alle patienten die dit onderzoek hebben mogelijk gemaakt!
Lieve vrienden en vriendinnen, dank jullie wel voor jullie betrokkenheid en steun!
Lieve Yolande en Pieter (& Suzanna, Sophie en Steven): mede door jullie is Rotterdam mijn 
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Lieve Jochem en Frithjof, ondanks de afstand die ons vaak scheidt, staan wij dichtbij elkaar. 
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